<html xmlns="http://www.w3.org/1999/xhtml"> <head> <style type="text/css">
      	     		 
      	    a                          {background : #ffffff; }
      	    article                    {border-style : dotted; border-width : 2px; }
		 	
		 	div                        {background : #ffffcc;}
		 	div.abstract-title         {font-weight : bold ; font-size : 16pt;}
		 	div.ack                    {border-style : solid ; border-color : red; margin : 2em; }
		 	div.article-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.boxed-text             {margin : 5em; border-style : solid;}
		 	div.contrib-group          {margin : 1em; }
		 	div.fig                    {border-style : solid; border-width : 2px; margin : 2em; }
		 	div.funding                {font-weight : bold ; font-size : 16pt;}
		 	div.given-names            {font-style : italic;}
		 	div.intro                  {border-style : inset; margin : 5px;}
		 	div.introduction           {border-style : inset; margin : 5px;}
		 	div.journal-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.journal-title-group    {background : #ffeeee;}
		 	div.article-title          {font-weight : bold ; font-size : 18pt;}
		 	div.kwd                    {font-style : italic}
		 	div.meta-name              {font-weight : bold ; font-size : 16pt;}
		 	div.name                   {font-weight : bold;}
		 	div.alt-title              {font-style : italic; font-size : 12px;}
		 	
		 	div.sec                    {border : 2px; margin 5px; padding 2px;}
		 	div.title                  {font-family : courier; font-weight : bold;
		 	                            font-size : 16pt; margin : 5px;}
		 	
		 	div.materials_methods      {border-style : double; margin : 5px; }
		 	div.methods                {border-style : double; margin : 5px; }
		 	
		 	div.results                {border-style : solid; margin : 5px;}
		 	div.background             {border-style : dotted; margin : 5px;}
		 	
		 	div.discussion             {border-style : groove; margin : 5px;}
		 	div.conclusion             {border-style : ridge; margin : 5px;}
		 	div.conclusions             {border-style : ridge; margin : 5px;}
		 	div.supplementary-material {border-style : inset; margin : 5px;}
		 	div.abbreviations          {border-style : double; border-color : red; margin : 5px;}
		 	div.competinginterests     {border-style : double; border-color : blue; margin : 5px;}
		 	div.acknowledgements       {border-style : double; border-color : green; margin : 5px;}
		 	div.authors_contributions   {border-style : double; border-color : purple; margin : 5px;}
		 	
		 	div.publisher              {border-style : outset; margin : 5px;}
		 	div.fn-type-conflict       {background : #f88; }
		 	div.fn-type-con            {background : #ddf; }
		 	div.fn-type-other          {background : #ddd; }
		 	
		 	div.unknown                {background : #ffd;
									 	  border-style : solid;
									 	  border-width : 1px;
									 	  padding : 2 px;}
		 	  
      	    table                      {background : #ffffdd;}
		 	tr                         {background : #ddddff; padding : 1px;}
		 	
		 	span                       {background : #ffcccc;}
		 	
		 	span.citation-author       {font-family : helvetica; background : #ffeeee;}
		 	span.collab                {background : #ddffff; }
		 	span.comment               {font-family : courier; font-size : 6px; background : #ffaaff;}
		 	span.contrib               {background : #ffffff;}
		 	span.corresp               {background : #ddffdd; }
		 	span.doi                   {background : #ffffff;}
		 	span.email                 {font-family : courier; }
		 	span.etal                  {font-style : italic;}
		 	span.fpage                 {font-family : courier;}
		 	span.given-names           {background : #ffffff;}
		 	span.iso-abbrev            {background : #ffffff;}
		 	span.issn-epub             {background : #ffffff;}
		 	span.issn-ppub             {background : #ffffff;}
		 	span.journal-title         {background : #ffffff;}
		 	span.lpage                 {font-family : courier;}
		 	span.mixed-article-title   {font-style : italic ;}
		 	span.nlm-ta                {background : #ffffff;}
		 	span.pmc                   {background : #ffffff;}
		 	span.pmcid                 {background : #ffffff;}
		 	span.pmid                  {background : #ffffff;}
		 	span.publisher             {background : #ffffff;}
		 	span.publisher-id          {background : #ffffff;}
		 	span.publisher-name        {background : #ffffff;}
		 	span.source                {background : #ffffff;}
		 	span.subject               {background : #ffffff;}
		 	span.surname               {background : #ffffff;}
		 	span.volume                {font-family : courier; font-weight : bold;}
		 	span.year                  {font-family : courier ; font-style : italic;}
			</style> </head> <body> <div class="front" title="front"> <div class="journal-meta" tagx="journal-meta" title="journal-meta"><span class="nlm-ta" title="nlm-ta">J Enzyme Inhib Med Chem</span><span class="iso-abbrev" title="iso-abbrev">J Enzyme Inhib Med Chem</span><div class="journal-title-group" tagx="journal-title-group" title="journal-title-group"><span class="journal-title" tagx="journal-title" title="journal-title">Journal of Enzyme Inhibition and Medicinal Chemistry</span></div><span class="issn-ppub" tagx="issn" title="issn-ppub">1475-6366</span><span class="issn-epub" tagx="issn" title="issn-epub">1475-6374</span><div class="publisher" tagx="publisher" title="publisher"><span class="publisher-name" tagx="publisher-name" title="publisher-name">Taylor &amp;amp; Francis</span></div> </div> <div class="article-meta" tagx="article-meta" title="article-meta"><span class="pmcid" title="pmcid"> pmcid: <a href="http://www.ncbi.nlm.nih.gov/pubmed/7758046">7758046</a></span><span class="pmid" title="pmid"> pmid: <a href="http://www.ncbi.nlm.nih.gov/pubmed/33349069">33349069</a></span><span class="doi" title="doi"> doi: <a href="https://dx.doi.org/10.1080/14756366.2020.1861606">10.1080/14756366.2020.1861606</a></span><span class="publisher-id" title="publisher-id">1861606</span><div class="unknown" title="article-version" tag="article-version">
Version of Record</div> <div class="article-categories" title="article-categories">
: <span class="subject" title="subject">Research Article</span>: <span class="subject" title="subject">Research Paper</span></div> <div class="title-group" tagx="title-group" title="title-group"> <div class="article-title" title="article-title">
Novel piperazineâ€"chalcone hybrids and related pyrazoline analogues targeting VEGFR-2 kinase; design, synthesis, molecular docking studies, and anticancer evaluation</div> <div class="alt-title" title="alt-title">
M. F. Ahmed et al.</div> </div> <div class="contrib-group" title="contrib-group"><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ahmed</span><span class="given-names" tagx="given-names" title="given-names">Marwa F.</span></span><a href="#AF0001">a</a><a href="#AF0002">b</a><a href="#AN0002" /></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Santali</span><span class="given-names" tagx="given-names" title="given-names">Eman Y.</span></span><a href="#AF0001">a</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">El-Haggar</span><span class="given-names" tagx="given-names" title="given-names">Radwan</span></span><a href="#AF0002">b</a><a href="#AN0001" /></span><span class="citation_author_institution" id="AF0001">[a], <span class="institution" title="institution">Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Taif University</span><span class="city" tagx="city" title="city">Taif</span><span class="country" tagx="country" title="country">Kingdom of Saudi Arabia</span></span><span class="citation_author_institution" id="AF0002">[b], <span class="institution" title="institution">Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Helwan University</span><span class="city" tagx="city" title="city">Cairo</span><span class="country" tagx="country" title="country">Egypt</span></span></div> <div class="author-notes" title="author-notes"> <div class="fn-type-" title=""> <p content-type="appended text">Supplemental data for this article can be accessed <a href="https://doi.org/10.1080/14756366.2020.1861606"><u>here</u></a>.</p> </div> <div class="corresp" title="corresp">
CONTACT Radwan El-Haggar <span class="email" tagx="email" title="email">radwan_elhaggar@pharm.helwan.edu.eg</span><span class="institution" title="institution">Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Helwan University</span>, <span class="city" tagx="city" title="city">Cairo</span>, <span class="postal-code" tagx="postal-code" title="postal-code">11795</span>, <span class="country" tagx="country" title="country">Egypt</span></div> <div class="corresp" title="corresp">
Marwa F. Ahmed <span class="email" tagx="email" title="email">marwa.farg@tu.edu.sa</span><span class="institution" title="institution">Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Taif University</span>, <span class="city" tagx="city" title="city">Taif</span>, <span class="postal-code" tagx="postal-code" title="postal-code">21974</span>, <span class="country" tagx="country" title="country">Kingdom of Saudi Arabia</span></div> </div><span class="pub-date-" title="pub-date-">: <span>2020-12-12</span></span><span class="pub-date-" title="pub-date-">: <span>2021</span></span><span class="volume" tagx="volume" title="volume">36</span><span class="issue" tagx="issue" title="issue">1</span><span class="fpage" tagx="fpage" title="fpage">307</span><span class="lpage" tagx="lpage" title="lpage">318</span><div class="permissions"><span class="copyright" title="copyright">(C) <span class="copyright-holder" tagx="copyright-holder" title="copyright-holder">The Author(s)</span>, <span class="copyright-year" tagx="copyright-year" title="copyright-year">2020</span></span><span class="license" title="license"><span class="license-p" title="license-p">This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<a href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</a>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</span></span></div><a class="self-uri" href="IENZ_36_1861606.pdf" title="self-uri">IENZ_36_1861606.pdf</a><div class="abstract" title="abstract"> <div class="abstract-title" title="abstract-title">
Abstract</div> <div class="title" tagx="title" title="title">
Abstract</div> <p>New piperazineâ€"chalcone hybrids and related pyrazoline derivatives have been designed and synthesised as potential vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors. The National Cancer Institute (NCI) has selected six compounds to evaluate their antiproliferative activity <i>inÂ vitro</i> against 60 human cancer cells lines. Preliminary screening of the examined compounds indicated promising anticancer activity against number of cell lines. The enzyme inhibitory activity against VEGFR-2 was evaluated and IC<sub>50</sub> of the tested compounds ranged from 0.57â€‰ÂµM to 1.48â€‰ÂµM. The most potent derivatives <b>Vd</b> and <b>Ve</b> were subjected to further investigations. A cell cycle analysis showed that both compounds mainly arrest HCT-116 cell cycle in the G2/M phase. Annexin V-FITC apoptosis assay showed that <b>Vd</b> and <b>Ve</b> induced an approximately 18.7-fold and 21.2-fold total increase in apoptosis compared to the control. Additionally, molecular docking study was performed against VEGFR (PDB ID: 4ASD) using MOE 2015.10 software and <b>Sorafenib</b> as a reference ligand.</p> </div> <div class="abstract" title="abstract"> <div class="title" tagx="title" title="title">
Graphical Abstract</div> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/" /></div>  </div> </div> <div class="kwd-group"> <div class="title" tagx="title" title="title">
Keywords</div> <div class="kwd" title="kwd">
antitumor</div> <div class="kwd" title="kwd">
vascular endothelial growth factor receptor</div> <div class="kwd" title="kwd">
molecular docking</div> </div> <div class="counts" title="counts"><span class="fig-count" title="fig-count">fig-count: </span><span class="table-count" title="table-count">table-count: </span><span class="page-count" title="page-count">page-count: </span><span class="word-count" title="word-count">word-count: </span></div> </div> </div> <div class="body" title="body"> <div class="introduction" title="sec"><span class="label" tagx="label" title="label">1.</span><div class="title" tagx="title" title="title">
Introduction</div> <p>Cancer is a major global health problem characterised by uncontrolled growth of abnormal cells. Although cancer research resulted in a range of innovative and promising approaches, the medications used as therapies have strong drawbacks and cancer is expected to be the leading cause of death in the future<a href="#CIT0001"><sup>1â€"3</sup></a>. Targeted cancer treatments have recently been approved to treat specific cancers such as melanoma, renal, colon, lung, ovary, central nervous system, breast, and leukaemia<a href="#CIT0004"><sup>4</sup></a>. Targeted chemotherapy requires several strategies, including angiogenesis inhibition, which has proved to be a successful technique for tumour growth<a href="#CIT0005"><sup>5</sup></a>. Angiogenesis is an important physiological process in which the pre-existing vessels form new blood vessels. It is a vital physiological process that happens during inflammation and wound healing<a href="#CIT0006"><sup>6</sup></a><sup>,</sup><a href="#CIT0007"><sup>7</sup></a>. New blood vessels penetrate tumour masses and provide them with oxygen and nutrients which promote tumour progression and metastasis in pathological angiogenesis<a href="#CIT0008"><sup>8</sup></a>. Therefore, blocking angiogenesis could be a promising strategy to inhibit growth of tumours with lower adverse effects than other typical chemotherapies<a href="#CIT0005"><sup>5</sup></a>.</p> <p>The vascular endothelial growth factor (VEGF) isoforms were particularly attractive targets to inhibit angiogenesis<a href="#CIT0009"><sup>9</sup></a><sup>,</sup><a href="#CIT0010"><sup>10</sup></a>. The expression of VEGF during embryonic stages is high and is thought to play a crucial role in new (vasculogenesis) or pre-existing blood vessels (angiogenesis)<a href="#CIT0011"><sup>11</sup></a>. For certain solid tumours, overexpression of VEGF contributes to increased tumour growth and metastasis, which may be attributed to improved nutrient replenishment availability for the metabolising cell<a href="#CIT0012"><sup>12</sup></a><sup>,</sup><a href="#CIT0013"><sup>13</sup></a>. Vascular endothelial growth factor receptor-2 (VEGFR-2) is a subtype of tyrosine kinase receptor VEGF family (VEGFR-TK)<a href="#CIT0014"><sup>14</sup></a><sup>,</sup><a href="#CIT0015"><sup>15</sup></a>. It is responsible for normal and abnormal changes in vascular endothelial cells<a href="#CIT0016"><sup>16</sup></a><sup>,</sup><a href="#CIT0017"><sup>17</sup></a>. VEGFR-2 inhibition will affect tumour cell blood supply, inhibiting its development, proliferation, and metastasis. VEGFR signalling pathway inhibition is a key therapeutic target for tumour inhibition<a href="#CIT0018"><sup>18</sup></a><sup>,</sup><a href="#CIT0019"><sup>19</sup></a>.</p> <p>N-aryl piperazine derivatives are important organic compounds that have recently attracted considerable interest for their anti-cancer activity<a href="#CIT0020"><sup>20â€"23</sup></a>. On the other hand, pyrazole a simple aromatic five-membered ring contains two adjacent nitrogen atoms is included in many derivatives that display a variety of pharmacological activities such as anti-Alzheimer disease<a href="#CIT0024"><sup>24</sup></a>, anticonvulsant<a href="#CIT0025"><sup>25</sup></a><sup>,</sup><a href="#CIT0026"><sup>26</sup></a>, anti-tubercular<a href="#CIT0027"><sup>27</sup></a><sup>,</sup><a href="#CIT0028"><sup>28</sup></a>, anti-microbial<a href="#CIT0029"><sup>29</sup></a><sup>,</sup><a href="#CIT0030"><sup>30</sup></a>, anti-inflammatory, and analgesic<a href="#CIT0031"><sup>31</sup></a><sup>,</sup><a href="#CIT0032"><sup>32</sup></a>. Numerous pyrazole derivatives have proved their anti-cancer efficacy against different types of cancer<a href="#CIT0033"><sup>33â€"38</sup></a>. Chalcones, (1,3-diaryl-2-propene-1-ones) derivatives that can conventionally be synthesised by Claisenâ€"Schmidt condensation<a href="#CIT0039"><sup>39</sup></a> remained a curiosity among researchers due to their diversified biological activities<a href="#CIT0040"><sup>40</sup></a>, such as antimalarial<a href="#CIT0041"><sup>41</sup></a>, anti-histaminic<a href="#CIT0042"><sup>42</sup></a>, anti-diabetic<a href="#CIT0043"><sup>43</sup></a>, anti-inflammatory<a href="#CIT0044"><sup>44</sup></a>, and anti-neoplastic activity<a href="#CIT0045"><sup>45</sup></a><sup>,</sup><a href="#CIT0046"><sup>46</sup></a>.</p> <p>On the other hand, many chalcone derivatives (compound <b>1</b><a href="#CIT0047"><sup>47</sup></a>, compound <b>2</b><a href="#CIT0048"><sup>48</sup></a>, and compound <b>3</b><a href="#CIT0049"><sup>49</sup></a>) along with pyrazole derivatives (compound <b>4</b><a href="#CIT0050"><sup>50</sup></a> and compound <b>5</b><a href="#CIT0051"><sup>51</sup></a>) and piperazine derivatives (compound <b>6</b><a href="#CIT0052"><sup>52</sup></a> and compound <b>7</b><a href="#CIT0053"><sup>53</sup></a>) display potential inhibitory activity of VEGFR-2 kinase which is an essential factor in angiogenesis (<a href="#F0001">Figure 1</a>). Thus, chalcone and analogues demonstrated potential inhibitory activity of VEGFR could be considered as important cancer prevention targets<a href="#CIT0054"><sup>54â€"56</sup></a>.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 1.</span></a></div>   <p>Examples of chalcones, pyrazoles, and piperazine derivatives as VEGFR inhibitors.</p>   </div> <p>Molecular hybridisation is one of the effective chemotherapeutic agent production techniques that require the synthesis of two distinct bioactive units. In the present research, the design and synthesis of novel hybrid compounds bearing piperazine and chalcone or piperazine and pyrazoline (<a href="#F0002">Figure 2</a>) are our target. Newly synthesised compounds have been submitted for evaluation of their anticancer activity to the National Cancer Institute (NCI). Six compounds were selected by NCI, and 60 lines of human cancer cells were screened <i>inÂ vitro</i>. The inhibitory activity had been also tested against VEGFR-2.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 2.</span></a></div>   <p>Design of newly synthesised derivatives as VEGFR inhibitor.</p>   </div> </div> <div class="resultsanddiscussion" title="sec"><span class="label" tagx="label" title="label">2.</span><div class="title" tagx="title" title="title">
Results and discussion</div> <div class="chemistry" title="sec"><span class="label" tagx="label" title="label">2.1.</span><div class="title" tagx="title" title="title">
Chemistry</div> <p>Compounds <b>Vaâ€"h</b> were synthesised via the reaction of 4â€²-piperazino-acetophenone <b>III</b> and the appropriate aldehyde (<a href="#s0001">Scheme 1</a>). The reaction of the chalcone <b>Va</b>, <b>Ve</b>, and <b>Vf</b> and hydrazine hydrate afforded pyrazoline derivatives <b>VIaâ€"c</b> (<a href="#s0002">Scheme 2</a>). The structures of all newly synthesised compounds were confirmed by various methods of spectroscopic analysis, such as <sup>1</sup>H NMR, <sup>13</sup>C NMR, IR, and mass spectrometry.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Scheme 1.</span></a></div>   <p>Synthesis of target compounds <b>Vaâ€"h</b>. Reagents and conditions: (i) DMSO, heating at 110â€‰Â°C, 24â€‰h; (ii) alcoholic NaOH (10%), stirring 5â€‰h.</p>   </div> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Scheme 2.</span></a></div>   <p>Synthesis of target compounds <b>VIaâ€"c</b>. Reagents and conditions: (i) hydrazine hydrate, absolute ethanol, reflux 12â€‰h.</p>   </div> </div> <div class="biologicalactivity" title="sec"><span class="label" tagx="label" title="label">2.2.</span><div class="title" tagx="title" title="title">
Biological activity</div> <div class="screeningofanticanceractivity" title="sec"><span class="label" tagx="label" title="label">2.2.1.</span><div class="title" tagx="title" title="title">
Screening of anticancer activity</div> <p>Six compounds were selected by the NCI, according to NCIâ€™s DTP selection guidelines<a href="#CIT0057"><sup>57</sup></a>, for evaluation of their anticancer activity at a single-dose of 10Â ÂµM against 60 human tumours cell lines. The compoundsâ€™ screening findings are summarised in <a href="#t0001">Table 1</a>. Data analysis resulting from the primary assay showed that chalcone derivatives <b>Vd</b>, <b>Ve</b>, and <b>Vf</b> showed moderate to good inhibitory activity mainly against leukaemia and colon cancer cell lines.</p> <div class="table-wrap_UNKNOWN" id="t0001" orientation="portrait" position="float"><span class="label" tagx="label" title="label">Table 1.</span> <p><i>In vitro</i> growth inhibitory percent for compounds <b>Vd</b>, <b>Ve</b>, <b>Vf</b>, <b>VIa</b>, <b>VIb</b>, and <b>VIc</b> at 10Â ÂµM concentration, towards the 60 subpanel cancer cell lines, results were given as a percentage of cell growth promotion.</p>  <table frame="hsides" rules="groups"> <colgroup> <col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup>  <thead> <tr> <th align="left">Panel</th> <th align="center">Subpanel</th> <th align="center">Vd</th> <th align="center">Ve</th> <th align="center">Vf</th> <th align="center">VIa</th> <th align="center">VIb</th> <th align="center">VIc</th> </tr> </thead> <tbody valign="top"> <tr> <td rowspan="6">Leukaemia</td> <td align="left">CCRF-CEM</td> <td align="char" char=".">58.18</td> <td align="char" char=".">22.15</td> <td align="char" char=".">78.16</td> <td align="char" char=".">71.21</td> <td align="char" char=".">69.44</td> <td align="char" char=".">80.81</td> </tr> <tr> <td align="left">HL-60(TB)</td> <td align="char" char=".">60.38</td> <td align="char" char=".">28.91</td> <td align="char" char=".">79.28</td> <td align="char" char=".">81.63</td> <td align="char" char=".">76.95</td> <td align="char" char=".">77.32</td> </tr> <tr> <td align="left">K-562</td> <td align="char" char=".">16.55</td> <td align="char" char=".">12.37</td> <td align="char" char=".">85.84</td> <td align="char" char=".">78.12</td> <td align="char" char=".">58.92</td> <td align="char" char=".">77.92</td> </tr> <tr> <td align="left">MOLT-4</td> <td align="char" char=".">68.62</td> <td align="char" char=".">80.75</td> <td align="char" char=".">91.63</td> <td align="char" char=".">96.02</td> <td align="char" char=".">72.10</td> <td align="char" char=".">74.15</td> </tr> <tr> <td align="left">RPMI-8226</td> <td align="char" char=".">76.47</td> <td align="char" char=".">49.59</td> <td align="char" char=".">97.33</td> <td align="char" char=".">88.98</td> <td align="char" char=".">72.01</td> <td align="char" char=".">92.51</td> </tr> <tr> <td align="left">SR</td> <td align="char" char=".">55.72</td> <td align="char" char=".">46.22</td> <td align="char" char=".">92.99</td> <td align="char" char=".">94.43</td> <td align="char" char=".">67.42</td> <td align="char" char=".">90.38</td> </tr> <tr> <td rowspan="9">Non-small cell lung cancer</td> <td align="left">A549/ATCC</td> <td align="char" char=".">76.84</td> <td align="char" char=".">67.25</td> <td align="char" char=".">78.75</td> <td align="char" char=".">78.06</td> <td align="char" char=".">68.21</td> <td align="char" char=".">76.20</td> </tr> <tr> <td align="left">EKVX</td> <td align="char" char=".">95.54</td> <td align="char" char=".">97.12</td> <td align="char" char=".">99.11</td> <td align="char" char=".">101.50</td> <td align="char" char=".">95.41</td> <td align="char" char=".">91.04</td> </tr> <tr> <td align="left">HOP-62</td> <td align="char" char=".">80.17</td> <td align="char" char=".">101.42</td> <td align="char" char=".">102.01</td> <td align="char" char=".">86.44</td> <td align="char" char=".">86.01</td> <td align="char" char=".">83.16</td> </tr> <tr> <td align="left">HOP-92</td> <td align="char" char=".">58.41</td> <td align="char" char=".">55.00</td> <td align="char" char=".">82.34</td> <td align="char" char=".">83.18</td> <td align="char" char=".">57.13</td> <td align="char" char=".">72.42</td> </tr> <tr> <td align="left">NCI-H226</td> <td align="char" char=".">87.11</td> <td align="char" char=".">86.54</td> <td align="char" char=".">99.71</td> <td align="char" char=".">93.10</td> <td align="char" char=".">89.08</td> <td align="char" char=".">82.88</td> </tr> <tr> <td align="left">NCI-H23</td> <td align="char" char=".">77.30</td> <td align="char" char=".">92.63</td> <td align="char" char=".">102.52</td> <td align="char" char=".">91.73</td> <td align="char" char=".">75.49</td> <td align="char" char=".">83.85</td> </tr> <tr> <td align="left">NCI-H322M</td> <td align="char" char=".">75.26</td> <td align="char" char=".">73.01</td> <td align="char" char=".">96.26</td> <td align="char" char=".">98.35</td> <td align="char" char=".">89.15</td> <td align="char" char=".">89.29</td> </tr> <tr> <td align="left">NCI-H460</td> <td align="char" char=".">74.45</td> <td align="char" char=".">97.07</td> <td align="char" char=".">106.01</td> <td align="char" char=".">101.50</td> <td align="char" char=".">95.16</td> <td align="char" char=".">94.92</td> </tr> <tr> <td align="left">NCI-H522</td> <td align="char" char=".">71.57</td> <td align="char" char=".">61.19</td> <td align="char" char=".">78.82</td> <td align="char" char=".">69.51</td> <td align="char" char=".">66.27</td> <td align="char" char=".">81.93</td> </tr> <tr> <td rowspan="7">Colon cancer</td> <td align="left">COLO 205</td> <td align="char" char=".">96.91</td> <td align="char" char=".">83.00</td> <td align="char" char=".">111.89</td> <td align="char" char=".">113.04</td> <td align="char" char=".">93.87</td> <td align="char" char=".">95.69</td> </tr> <tr> <td align="left">HCC-2998</td> <td align="char" char=".">94.99</td> <td align="char" char=".">100.21</td> <td align="char" char=".">100.88</td> <td align="char" char=".">96.75</td> <td align="char" char=".">104.57</td> <td align="char" char=".">101.72</td> </tr> <tr> <td align="left">HCT-116</td> <td align="char" char=".">42.08</td> <td align="char" char=".">27.43</td> <td align="char" char=".">73.87</td> <td align="char" char=".">85.83</td> <td align="char" char=".">61.10</td> <td align="char" char=".">73.82</td> </tr> <tr> <td align="left">HCT-15</td> <td align="char" char=".">73.49</td> <td align="char" char=".">43.16</td> <td align="char" char=".">111.39</td> <td align="char" char=".">112.02</td> <td align="char" char=".">85.57</td> <td align="char" char=".">97.59</td> </tr> <tr> <td align="left">HT29</td> <td align="char" char=".">30.44</td> <td align="char" char=".">49.97</td> <td align="char" char=".">86.42</td> <td align="char" char=".">87.83</td> <td align="char" char=".">20.27</td> <td align="char" char=".">60.16</td> </tr> <tr> <td align="left">KM12</td> <td align="char" char=".">77.75</td> <td align="char" char=".">60.47</td> <td align="char" char=".">105.34</td> <td align="char" char=".">97.48</td> <td align="char" char=".">93.81</td> <td align="char" char=".">96.23</td> </tr> <tr> <td align="left">SW-620</td> <td align="char" char=".">61.08</td> <td align="char" char=".">50.69</td> <td align="char" char=".">105.59</td> <td align="char" char=".">94.11</td> <td align="char" char=".">91.67</td> <td align="char" char=".">93.46</td> </tr> <tr> <td rowspan="6">CNS cancer</td> <td align="left">SF-268</td> <td align="char" char=".">85.41</td> <td align="char" char=".">94.03</td> <td align="char" char=".">100.92</td> <td align="char" char=".">100.24</td> <td align="char" char=".">93.72</td> <td align="char" char=".">107.32</td> </tr> <tr> <td align="left">SF-295</td> <td align="char" char=".">101.78</td> <td align="char" char=".">95.92</td> <td align="char" char=".">101.95</td> <td align="char" char=".">103.66</td> <td align="char" char=".">97.70</td> <td align="char" char=".">98.00</td> </tr> <tr> <td align="left">SF-539</td> <td align="char" char=".">94.49</td> <td align="char" char=".">95.87</td> <td align="char" char=".">101.29</td> <td align="char" char=".">105.04</td> <td align="char" char=".">84.21</td> <td align="char" char=".">104.39</td> </tr> <tr> <td align="left">SNB-19</td> <td align="char" char=".">71.95</td> <td align="char" char=".">59.87</td> <td align="char" char=".">96.07</td> <td align="char" char=".">95.34</td> <td align="char" char=".">95.65</td> <td align="char" char=".">97.45</td> </tr> <tr> <td align="left">SNB-75</td> <td align="char" char=".">85.44</td> <td align="char" char=".">89.05</td> <td align="char" char=".">89.08</td> <td align="char" char=".">90.58</td> <td align="char" char=".">88.85</td> <td align="char" char=".">101.50</td> </tr> <tr> <td align="left">U251</td> <td align="char" char=".">72.39</td> <td align="char" char=".">67.21</td> <td align="char" char=".">95.03</td> <td align="char" char=".">94.54</td> <td align="char" char=".">78.59</td> <td align="char" char=".">95.06</td> </tr> <tr> <td rowspan="9">Melanoma</td> <td align="left">LOX IMVI</td> <td align="char" char=".">71.13</td> <td align="char" char=".">49.01</td> <td align="char" char=".">103.22</td> <td align="char" char=".">99.03</td> <td align="char" char=".">79.56</td> <td align="char" char=".">94.31</td> </tr> <tr> <td align="left">MALME-3M</td> <td align="char" char=".">94.15</td> <td align="char" char=".">112.40</td> <td align="char" char=".">99.98</td> <td align="char" char=".">106.87</td> <td align="char" char=".">102.13</td> <td align="char" char=".">93.43</td> </tr> <tr> <td align="left">M14</td> <td align="char" char=".">81.16</td> <td align="char" char=".">78.43</td> <td align="char" char=".">95.53</td> <td align="char" char=".">104.47</td> <td align="char" char=".">84.68</td> <td align="char" char=".">95.86</td> </tr> <tr> <td align="left">MDA-MB-435</td> <td align="char" char=".">94.27</td> <td align="char" char=".">80.14</td> <td align="char" char=".">102.37</td> <td align="char" char=".">102.57</td> <td align="char" char=".">101.87</td> <td align="char" char=".">105.18</td> </tr> <tr> <td align="left">SK-MEL-2</td> <td align="char" char=".">96.08</td> <td align="char" char=".">85.44</td> <td align="char" char=".">91.63</td> <td align="char" char=".">94.51</td> <td align="char" char=".">87.70</td> <td align="char" char=".">92.72</td> </tr> <tr> <td align="left">SK-MEL-28</td> <td align="char" char=".">109.03</td> <td align="char" char=".">106.02</td> <td align="char" char=".">115.56</td> <td align="char" char=".">114.17</td> <td align="char" char=".">109.51</td> <td align="char" char=".">115.80</td> </tr> <tr> <td align="left">SK-MEL-5</td> <td align="char" char=".">76.85</td> <td align="char" char=".">79.33</td> <td align="char" char=".">101.11</td> <td align="char" char=".">93.27</td> <td align="char" char=".">80.94</td> <td align="char" char=".">85.78</td> </tr> <tr> <td align="left">UACC-257</td> <td align="char" char=".">75.92</td> <td align="char" char=".">76.08</td> <td align="char" char=".">70.86</td> <td align="char" char=".">85.21</td> <td align="char" char=".">80.93</td> <td align="char" char=".">83.07</td> </tr> <tr> <td align="left">UACC-62</td> <td align="char" char=".">79.23</td> <td align="char" char=".">80.13</td> <td align="char" char=".">92.01</td> <td align="char" char=".">88.47</td> <td align="char" char=".">86.00</td> <td align="char" char=".">81.93</td> </tr> <tr> <td rowspan="7">Ovarian cancer</td> <td align="left">IGROV1</td> <td align="char" char=".">67.97</td> <td align="char" char=".">59.94</td> <td align="char" char=".">97.17</td> <td align="char" char=".">93.22</td> <td align="char" char=".">82.04</td> <td align="char" char=".">67.96</td> </tr> <tr> <td align="left">OVCAR-3</td> <td align="char" char=".">93.74</td> <td align="char" char=".">70.18</td> <td align="char" char=".">106.22</td> <td align="char" char=".">101.64</td> <td align="char" char=".">91.15</td> <td align="char" char=".">98.79</td> </tr> <tr> <td align="left">OVCAR-4</td> <td align="char" char=".">80.53</td> <td align="char" char=".">68.87</td> <td align="char" char=".">110.55</td> <td align="char" char=".">101.39</td> <td align="char" char=".">91.49</td> <td align="char" char=".">108.25</td> </tr> <tr> <td align="left">OVCAR-5</td> <td align="char" char=".">94.72</td> <td align="char" char=".">121.73</td> <td align="char" char=".">111.84</td> <td align="char" char=".">113.63</td> <td align="char" char=".">101.51</td> <td align="char" char=".">111.45</td> </tr> <tr> <td align="left">OVCAR-8</td> <td align="char" char=".">67.16</td> <td align="char" char=".">57.23</td> <td align="char" char=".">95.35</td> <td align="char" char=".">90.36</td> <td align="char" char=".">84.09</td> <td align="char" char=".">95.06</td> </tr> <tr> <td align="left">NCI/ADR-RES</td> <td align="char" char=".">109.37</td> <td align="char" char=".">79.31</td> <td align="char" char=".">107.53</td> <td align="char" char=".">102.72</td> <td align="char" char=".">104.69</td> <td align="char" char=".">106.03</td> </tr> <tr> <td align="left">SK-OV-3</td> <td align="char" char=".">79.98</td> <td align="char" char=".">87.98</td> <td align="char" char=".">96.68</td> <td align="char" char=".">96.47</td> <td align="char" char=".">83.58</td> <td align="char" char=".">85.00</td> </tr> <tr> <td rowspan="8">Renal cancer</td> <td align="left">786-0</td> <td align="char" char=".">85.24</td> <td align="char" char=".">87.22</td> <td align="char" char=".">103.38</td> <td align="char" char=".">106.73</td> <td align="char" char=".">94.50</td> <td align="char" char=".">111.09</td> </tr> <tr> <td align="left">A498</td> <td align="char" char=".">95.14</td> <td align="char" char=".">100.79</td> <td align="char" char=".">97.22</td> <td align="char" char=".">93.08</td> <td align="char" char=".">90.59</td> <td align="char" char=".">97.17</td> </tr> <tr> <td align="left">ACHN</td> <td align="char" char=".">84.70</td> <td align="char" char=".">68.11</td> <td align="char" char=".">113.06</td> <td align="char" char=".">104.24</td> <td align="char" char=".">101.47</td> <td align="char" char=".">99.87</td> </tr> <tr> <td align="left">CAKI-1</td> <td align="char" char=".">68.63</td> <td align="char" char=".">79.37</td> <td align="char" char=".">86.18</td> <td align="char" char=".">83.12</td> <td align="char" char=".">86.62</td> <td align="char" char=".">80.62</td> </tr> <tr> <td align="left">RXF 393</td> <td align="char" char=".">75.94</td> <td align="char" char=".">101.92</td> <td align="char" char=".">97.78</td> <td align="char" char=".">108.30</td> <td align="char" char=".">95.32</td> <td align="char" char=".">104.89</td> </tr> <tr> <td align="left">SN12C</td> <td align="char" char=".">68.16</td> <td align="char" char=".">57.67</td> <td align="char" char=".">99.00</td> <td align="char" char=".">98.09</td> <td align="char" char=".">83.08</td> <td align="char" char=".">89.56</td> </tr> <tr> <td align="left">TK-10</td> <td align="char" char=".">114.19</td> <td align="char" char=".">101.24</td> <td align="char" char=".">95.83</td> <td align="char" char=".">130.17</td> <td align="char" char=".">113.60</td> <td align="char" char=".">122.80</td> </tr> <tr> <td align="left">UO-31</td> <td align="char" char=".">76.58</td> <td align="char" char=".">58.35</td> <td align="char" char=".">89.78</td> <td align="char" char=".">86.28</td> <td align="char" char=".">76.56</td> <td align="char" char=".">77.18</td> </tr> <tr> <td rowspan="2">Prostate cancer</td> <td align="left">PC-3</td> <td align="char" char=".">66.01</td> <td align="char" char=".">51.40</td> <td align="char" char=".">73.56</td> <td align="char" char=".">83.35</td> <td align="char" char=".">64.23</td> <td align="char" char=".">70.34</td> </tr> <tr> <td align="left">DU-145</td> <td align="char" char=".">77.70</td> <td align="char" char=".">105.61</td> <td align="char" char=".">108.14</td> <td align="char" char=".">104.00</td> <td align="char" char=".">103.62</td> <td align="char" char=".">107.16</td> </tr> <tr> <td rowspan="6">Breast cancer</td> <td align="left">MCF7</td> <td align="char" char=".">51.72</td> <td align="char" char=".">34.68</td> <td align="char" char=".">99.38</td> <td align="char" char=".">93.05</td> <td align="char" char=".">68.65</td> <td align="char" char=".">73.03</td> </tr> <tr> <td align="left">MDA-MB-231/ATCC</td> <td align="char" char=".">73.60</td> <td align="char" char=".">94.50</td> <td align="char" char=".">98.76</td> <td align="char" char=".">95.96</td> <td align="char" char=".">81.98</td> <td align="char" char=".">84.58</td> </tr> <tr> <td align="left">HS 578T</td> <td align="char" char=".">79.41</td> <td align="char" char=".">91.26</td> <td align="char" char=".">99.19</td> <td align="char" char=".">91.67</td> <td align="char" char=".">84.17</td> <td align="char" char=".">89.15</td> </tr> <tr> <td align="left">BT-549</td> <td align="char" char=".">73.16</td> <td align="char" char=".">66.42</td> <td align="char" char=".">90.81</td> <td align="char" char=".">96.87</td> <td align="char" char=".">70.80</td> <td align="char" char=".">85.33</td> </tr> <tr> <td align="left">T-47D</td> <td align="char" char=".">87.54</td> <td align="char" char=".">74.40</td> <td align="char" char=".">118.12</td> <td align="char" char=".">89.99</td> <td align="char" char=".">73.62</td> <td align="char" char=".">82.20</td> </tr> <tr> <td align="left">MDA-MB-468</td> <td align="char" char=".">94.85</td> <td align="char" char=".">46.48</td> <td align="char" char=".">100.32</td> <td align="char" char=".">101.01</td> <td align="char" char=".">96.57</td> <td align="char" char=".">114.26</td> </tr> </tbody> </table> </div> <p>As illustrated in <a href="#t0001">Table 1</a>, compound <b>Vf</b> bearing 3-fluoropyridine moiety showed weak anti-proliferative activity against non-small cell lung cancer HOP-92, leukaemia K-562, colon cancer HT29, leukaemia SR, and breast cancer MCF7 cancer cell lines, with cell growth promotion (82.34%, 85.84%, 86.42%, 92.99%, 99.38%; cell growth inhibition: 17.66%, 14.16%, 13.85%, 7.01%, and 0.62%, respectively). It also showed moderate activity against leukaemia HL-60(TB) (cell growth promotion 79.28%; cell growth inhibition: 20.72%), leukaemia CCRF-CEM (78.16%; cell growth inhibition: 21.84%), and colon cancer HCT-116 (cell growth promotion 73.87%; cell growth inhibition: 26.13%).</p> <p>Replacing 3-fluoropyridine of compound <b>Vf</b> with 3-fluorophenyl moiety, compound <b>Vd</b> significantly increased growth inhibition against number of cancer cell lines, such as leukaemia HL-60(TB), non-small cell lung cancer HOP-92, leukaemia CCRF-CEM, leukaemia SR, and breast cancer MCF7 with percent growth inhibition of 39.17%, 41.59%, 41.82%, 44.28%, and 48.28%, respectively, compared to that of compound <b>Vf</b> (20.72%, 17.66%, 21.84%, 7.01%, and 0.62%, respectively). In addition, compound <b>Vd</b>, showed good to excellent activity against colon cancer HCT-116, colon cancer HT29, and leukaemia K-562 with percent growth inhibition of 57.92%, 69.56%, and 83.45%, respectively.</p> <p>Furthermore, replacing 3-fluorophenyl moiety with 4-fluoro-3-methoxyphenyl moiety compound <b>Ve</b> markedly increase growth inhibition towards many cancer cell lines. It showed cell growth promotion for non-small cell lung cancer HOP-92 (55.00%; cell growth inhibition: 45.00%), leukaemia SR (46.22%; cell growth inhibition: 53.78%), breast cancer MCF7 (34.68%; cell growth inhibition: 65.32%), leukaemia HL-60(TB) (28.91%; cell growth inhibition: 71.09%), colon cancer HCT-116 (27.43%; cell growth inhibition: 72.57%), leukaemia CCRF-CEM (22.15%; cell growth inhibition: 77.85%), and leukaemia K-562 (12.37%; cell growth inhibition: 87.63%). From previous results, we can conclude that chalcone derivative bearing 4-fluoro-3-methoxyphenyl moiety (<b>Ve</b>) was the most potent chalcone towards leukaemia CCRF-CEM, leukaemia HL-60(TB), leukaemia K-562, leukaemia SR non-small cell lung cancer HOP-92, colon cancer HCT-116, and breast cancer MCF7 cell lines.</p> <p>On the other hand, pyrazole analogues <b>VIa</b>, <b>VIb</b>, and <b>VIc</b> showed promising cytotoxicity towards a variety of cancer cell lines. Compound <b>VIa</b> bearing benzonitrile moiety exhibited a weak growth inhibition against several cancer cell lines as it displayed cell growth promotion for leukaemia SR (94.43%; cell growth inhibition: 5.57%), colon cancer HT29 (87.83%; cell growth inhibition: 12.17%), colon cancer HCT-116 (85.83%; cell growth inhibition: 14.17%), and non-small cell lung cancer HOP-92 (83.18%; cell growth inhibition: 16.82%). In addition, it showed good inhibitory activity against many cancer cell lines with cell growth promotion for leukaemia K-562 (78.12%; cell growth inhibition: 21.88%), non-small cell lung cancer A549/ATCC (78.06%; cell growth inhibition: 21.94%), leukaemia CCRF-CEM (71.21%; cell growth inhibition: 28.79%), and non-small cell lung cancer NCI-H522 (69.51%; cell growth inhibition: 30.49%).</p> <p>Replacing benzonitrile moiety with 3-fluoropyridine moiety, compound <b>VIc</b> increased anti-proliferative activity against few cancer cell lines such as colon cancer HCT-116, non-small cell lung cancer HOP-92 and colon cancer HT29 with percent of cell growth inhibition of 26.18%, 27.58%, and 39.84%, respectively.</p> <p>Finally, compound <b>VIb</b> with 4-fluoro-3-methoxyphenyl moiety was the most potent pyrazole derivative and exhibited moderate to good inhibitory activity towards many cancer cell lines. It showed percent of cell growth promotion for colon cancer HCT-116, leukaemia K-562, non-small cell lung cancer HOP-92, and colon cancer HT29 of 61.10%, 58.92%, 57.13%, and 20.27%, respectively (cell growth inhibition: 38.9%, 41.08%, 42.87%, and 79.73%, respectively).</p> </div> <div class="vascularendothelialgrowthfactorreceptor-2inhibition" title="sec"><span class="label" tagx="label" title="label">2.2.2.</span><div class="title" tagx="title" title="title">
Vascular endothelial growth factor receptor-2 inhibition</div> <p>VEGFR is considered as an important target for the development of potential anti-cancer candidates<a href="#CIT0054"><sup>54â€"56</sup></a>. Therefore, compounds <b>Vd</b>, <b>Ve</b>, <b>Vf</b>, <b>VIa</b>, <b>VIb</b>, and <b>VIc</b> were further investigated for their ability to inhibit VEGFR-2 using colorimetric assay of human VEGFR-2 ELISA (enzyme-linked immunosorbent assay) and <b>Sorafenib</b> as a reference drug. Results were presented as half maximal inhibitory concentration (IC<sub>50</sub>) values (<a href="#t0002">Table 2</a>). IC<sub>50</sub> of the tested compounds ranged from 0.57â€‰ÂµM to 1.48â€‰ÂµM. Compound <b>Ve</b> was the most potent VEGFR-2 inhibitor among the tested compounds with an IC<sub>50</sub> value of 0.57â€‰ÂµM which was comparable to results of <b>Sorafenib</b> that had IC<sub>50</sub>=0.51â€‰ÂµM. In addition, compound <b>Vd</b> showed significant VEGFR-2 inhibitory activity with IC<sub>50</sub>=0.80â€‰ÂµM. These results supported that VEGFR-2 could be a possible target for anti-tumour activity of our tested compounds.</p> <div class="table-wrap_UNKNOWN" id="t0002" orientation="portrait" position="float"><span class="label" tagx="label" title="label">Table 2.</span> <p><i>In vitro</i> VEGFR-2 inhibitory assay.</p>  <table frame="hsides" rules="groups"> <colgroup> <col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup>  <thead> <tr> <th align="left">Compound</th> <th align="center">IC<sub>50</sub> (Î¼M)</th> </tr> </thead> <tbody valign="top"> <tr> <td align="left"><b>Vd</b></td> <td align="left">0.80</td> </tr> <tr> <td align="left"><b>Ve</b></td> <td align="left">0.57</td> </tr> <tr> <td align="left"><b>Vf</b></td> <td align="left">1.33</td> </tr> <tr> <td align="left"><b>VIa</b></td> <td align="left">1.48</td> </tr> <tr> <td align="left"><b>VIb</b></td> <td align="left">1.06</td> </tr> <tr> <td align="left"><b>VIc</b></td> <td align="left">1.31</td> </tr> <tr> <td align="left"><b>Sorafenib</b></td> <td align="left">0.51</td> </tr> </tbody> </table> <div class="table-wrap-foot_UNKNOWN"> <div class="fn-type-" title=""> <p>IC<sub>50</sub> values of compounds <b>Vd</b>, <b>Ve</b>, <b>Vf</b>, <b>VIa</b>, <b>VIb</b> and <b>VIc</b> and <b>Sorafenib</b> reference drug.</p> </div> </div> </div> </div> <div class="cellcycleanalysis" title="sec"><span class="label" tagx="label" title="label">2.2.3.</span><div class="title" tagx="title" title="title">
Cell cycle analysis</div> <p>Most of cytotoxic compounds exert their anti-proliferative effect via arresting the cell cycle at certain phase. Flow cytometric analysis is considered a valuable method for determining and analysing the cell cycle parameters<a href="#CIT0058"><sup>58</sup></a>. In this study, compounds <b>Vd</b> and <b>Ve</b> as the most potent derivatives were selected to explore their effect on cell cycle progression and induction of apoptosis in HCT-116 cell line using the standard concentration of 10â€‰ÂµM. The effect on the cell cycle distribution was assessed by a DNA flow cytometry analysis and the cell cycle parameters were compared to untreated control cells in HCT-116 cells which had been incubated with 10â€‰ÂµM of <b>Vd</b> and <b>Ve</b> compounds and the results are shown in <a href="#t0003">Table 3</a> and <a href="#F0003">Figure 3</a>. The results revealed that, the percentage of HCT-116 cells at G2/M phase markedly increased from 15.44% to 50.44% and 46.85% after incubation with compound <b>Vd</b> and <b>Ve</b>, respectively. On the other hand, the percentage of HCT-116 cells at G1 phase decreased from 54.38% in control to 21.78% for compound <b>Vd</b> and 24.57% for compound <b>Ve</b> indicating that compounds <b>Vd</b> and <b>Ve</b> induced cell arrest at G2/M phase. The percentage of cell death at pre-G1 phase for compounds <b>Vd</b> and <b>Ve</b> was 16.54% and 18.22%, respectively.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 3.</span></a></div>   <p>Effect of compounds <b>Vd</b> and <b>Ve</b> on the phases of cell cycle of HCT-116 cells.</p>   </div> <div class="table-wrap_UNKNOWN" id="t0003" orientation="portrait" position="float"><span class="label" tagx="label" title="label">Table 3.</span> <p>Effect of compounds <b>Vd</b> and <b>Ve</b> on the phases of cell cycle of HCT-116 cells.</p>  <table frame="hsides" rules="groups"> <colgroup> <col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup>  <thead> <tr> <th align="left">Code</th> <th align="center">%G2/M</th> <th align="center">%S</th> <th align="center">%G0/G1</th> <th align="center">%Pre-G1</th> <th align="center">Comment</th> </tr> </thead> <tbody valign="top"> <tr> <td align="left"><b>Vd</b></td> <td align="left">50.44</td> <td align="char" char=".">27.78</td> <td align="char" char=".">21.78</td> <td align="char" char=".">16.54</td> <td align="left">cell cycle arrest@G2/M</td> </tr> <tr> <td align="left"><b>Ve</b></td> <td align="left">46.85</td> <td align="char" char=".">28.58</td> <td align="char" char=".">24.57</td> <td align="char" char=".">18.22</td> <td align="left">cell cycle arrest@G2/M</td> </tr> <tr> <td align="left">Control</td> <td align="left">15.44</td> <td align="char" char=".">30.18</td> <td align="char" char=".">54.38</td> <td align="char" char=".">1.97</td> <td align="left">Â </td> </tr> </tbody> </table> </div> </div> <div class="annexinv-fitcapoptosisassay" title="sec"><span class="label" tagx="label" title="label">2.2.4.</span><div class="title" tagx="title" title="title">
Annexin V-FITC apoptosis assay</div> <p>Double staining assay of annexin-V/propidium iodide (PI) was used to investigate the mode of induced HCT-116 cell death when treated with the tested compounds <b>Vd</b> and <b>Ve</b>. HCT-116 cells were treated for 24â€‰h with 10â€‰ÂµM from each tested compound. The results obtained are outlined in <a href="#t0004">Table 4</a> and <a href="#F0004">Figure 4</a>. The percentage of apoptosis caused by the <b>Vd</b> and <b>Ve</b> compounds respectively was (16.54 and 18.22). We can also conclude that in early stage treatment of HCT-116 cells with <b>Vd</b> and <b>Ve</b> compounds results in an increase in the percentage of apoptotic cells from 0.51% for control untreated cells to be 3.92 and 4.76, respectively. In late stage, the percentage of apoptotic cells was 10.32â€"11.35% compared to control (0.25%). The results indicate that the tested <b>Vd</b> and <b>Ve</b> induced apoptosis in HCT-116 cell line.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 4.</span></a></div>   <p>Effect of compounds <b>Vd</b> and <b>Ve</b> on the percentage of annexin V-FITC-positive staining in HCT-116 cells. The experiments were done in triplicates. The four quadrants identified as: LL: viable; LR: early apoptotic; UR: late apoptotic; UL: necrotic.</p>   </div> <div class="table-wrap_UNKNOWN" id="t0004" orientation="portrait" position="float"><span class="label" tagx="label" title="label">Table 4.</span> <p>Apoptosis and necrosis percent induced by compounds <b>Vd</b> and <b>Ve</b> in HCT-116 cells.</p>  <table frame="hsides" rules="groups"> <colgroup> <col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup>  <thead> <tr> <th rowspan="2" align="left">Â </th> <th colspan="3" align="center">Apoptosis <hr /> </th> <th rowspan="2" align="center">Necrosis</th> </tr> <tr> <th align="center">Total</th> <th align="center">Early</th> <th align="center">Late</th> </tr> </thead> <tbody valign="top"> <tr> <td align="left"><b>Vd</b></td> <td align="left">16.54</td> <td align="char" char=".">3.92</td> <td align="char" char=".">10.32</td> <td align="char" char=".">2.3</td> </tr> <tr> <td align="left"><b>Ve</b></td> <td align="left">18.22</td> <td align="char" char=".">4.76</td> <td align="char" char=".">11.35</td> <td align="char" char=".">2.11</td> </tr> <tr> <td align="left">Control</td> <td align="left">1.97</td> <td align="char" char=".">0.51</td> <td align="char" char=".">0.25</td> <td align="char" char=".">1.21</td> </tr> </tbody> </table> </div> </div> </div> <div class="moleculardocking" title="sec"><span class="label" tagx="label" title="label">2.3.</span><div class="title" tagx="title" title="title">
Molecular docking</div> <p>Molecular modelling is considered as an important tool to study molecular interactions of certain ligands and binding site of the corresponding protein. The ligandâ€"protein interaction behaviour at the active site was estimated based on the docking score function as implemented in MOE 2015.10<a href="#CIT0059"><sup>59</sup></a>. In this study, six active potential anticancer compounds <b>Vd</b>, <b>Ve</b>, <b>Vf</b>, <b>VIa</b>, <b>VIb</b>, and <b>VIc</b> were subjected to molecular docking studies using MOE program on the 3D structure of VEGFR using <b>Sorafenib</b> as reference compound. Binding free energy data obtained after the docking procedure showed that the tested compounds exhibit favourable docked complexes with the active site of target protein. The tested compounds <b>Vd</b>, <b>Ve</b>, <b>Vf</b>, <b>VIc</b>, <b>VIb</b>, and <b>VIc</b> exhibited interactions with the VEGFR active site to different extents and the docking score free energy of the tested compounds found to be this order: <b>Ve</b>&amp;gt;<b>VIa</b>&amp;gt;<b>Vd</b>&amp;gt;<b>Vf</b>&amp;gt;<b>VIc</b>&amp;gt;<b>VIb</b>, as shown in <a href="#t0005">Table 5</a>. Also, the other scoring parameters such as rmsd_refine, E_conf, E_place, and E_refine, indicated that the tested compounds were correctly docked in the biding site as the reference ligand <b>Sorafenib</b>.</p> <div class="table-wrap_UNKNOWN" id="t0005" orientation="portrait" position="float"><span class="label" tagx="label" title="label">Table 5.</span> <p>Docking energy scores (kcal/mol) derived from the MOE for compounds <b>Vd</b>â€"<b>f</b>, <b>VIa</b>â€"<b>c</b>, and the reference ligand <b>Sorafenib</b>.</p>  <table frame="hsides" rules="groups"> <colgroup> <col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup>  <thead> <tr> <th align="left">Comp. no.</th> <th align="center">Score</th> <th align="center">rmsd_refine</th> <th align="center">E_conf</th> <th align="center">E_place</th> <th align="center">E_score1</th> <th align="center">E_score2</th> <th align="center">E_refine</th> </tr> </thead> <tbody valign="top"> <tr> <td align="left"><b>Vd</b></td> <td align="char" char=".">â€"7.3974</td> <td align="char" char=".">2.6436</td> <td align="char" char=".">89.8860</td> <td align="char" char=".">â€"55.3257</td> <td align="char" char=".">â€"13.3058</td> <td align="char" char=".">â€"7.3974</td> <td align="char" char=".">â€"30.4426</td> </tr> <tr> <td align="left"><b>Ve</b></td> <td align="char" char=".">â€"7.9154</td> <td align="char" char=".">1.4800</td> <td align="char" char=".">118.5701</td> <td align="char" char=".">â€"66.3756</td> <td align="char" char=".">â€"12.5551</td> <td align="char" char=".">â€"7.9154</td> <td align="char" char=".">â€"33.5940</td> </tr> <tr> <td align="left"><b>Vf</b></td> <td align="char" char=".">â€"6.9883</td> <td align="char" char=".">1.5306</td> <td align="char" char=".">101.3355</td> <td align="char" char=".">â€"81.8762</td> <td align="char" char=".">â€"11.3026</td> <td align="char" char=".">â€"6.9883</td> <td align="char" char=".">â€"27.0719</td> </tr> <tr> <td align="left"><b>VIa</b></td> <td align="char" char=".">â€"7.4371</td> <td align="char" char=".">1.3288</td> <td align="char" char=".">121.3822</td> <td align="char" char=".">â€"71.7816</td> <td align="char" char=".">â€"13.2958</td> <td align="char" char=".">â€"7.4371</td> <td align="char" char=".">â€"20.1583</td> </tr> <tr> <td align="left"><b>VIb</b></td> <td align="char" char=".">â€"6.7455</td> <td align="char" char=".">0.9160</td> <td align="char" char=".">103.8081</td> <td align="char" char=".">â€"80.8748</td> <td align="char" char=".">â€"12.5471</td> <td align="char" char=".">â€"6.7455</td> <td align="char" char=".">â€"16.9364</td> </tr> <tr> <td align="left"><b>VIc</b></td> <td align="char" char=".">â€"6.9328</td> <td align="char" char=".">1.2209</td> <td align="char" char=".">99.4951</td> <td align="char" char=".">â€"46.3408</td> <td align="char" char=".">â€"11.6422</td> <td align="char" char=".">â€"6.9328</td> <td align="char" char=".">â€"22.0011</td> </tr> <tr> <td align="left"><b>Sorafenib</b></td> <td align="char" char=".">â€"11.1354</td> <td align="char" char=".">1.0623</td> <td align="char" char=".">â€"57.2969</td> <td align="char" char=".">â€"94.4447</td> <td align="char" char=".">â€"12.8634</td> <td align="char" char=".">â€"11.1354</td> <td align="char" char=".">â€"69.0130</td> </tr> </tbody> </table> <div class="table-wrap-foot_UNKNOWN"> <div class="fn-type-" title=""> <p>Score: lower scores are more favourable; rmsd_refine: the root mean square deviation of the pose from the docking pose compared to the co-crystal ligand position; E_conf: free binding energy of the conformer; E_place: free binding energy from the placement stage; E_score 1: free binding energy from the first rescoring stage; E_score 2: free binding energy from the second rescoring stage; E_refine: free binding energy from the refinement stage.</p> </div> </div> </div> <p>Based on the obtained scoring results, compounds <b>Ve</b>, <b>VIa</b>, and <b>Vd</b> showed the highest binding affinity to the VEGFR-2 active site. Compound <b>Ve</b> was the best among the synthesised compounds with docking score (â€"7.9154â€‰kcal/mol) compared to the reference ligand <b>Sorafenib</b> docking score (â€"11.1354â€‰kcal/mol), and it formed a direct interaction in the active site, similar to that of <b>Sorafenib</b>. Also, compounds <b>VIa</b> and <b>Vd</b> showed a good docking score (â€"7.4371â€‰kcal/mol) and (â€"7.3974â€‰kcal/mol), respectively, compared to <b>Sorafenib</b>. <a href="#F0005">Figure 5</a> reveals that the tested compounds <b>VIa</b> and <b>Vd</b> along with <b>Sorafenib</b> reacted with important amino acids in the active binding site. The carbonyl group of the chalcone moiety in both compounds <b>Ve</b> and <b>Vd</b> acts as H-bond acceptor and formed a H-bonding with LYS868 (<a href="#F0005">Figure 5(a,b)</a>). On the other hand, the reference compound <b>Sorafenib</b> formed several hydrogen bonding with the active side nearby amino acids GLU885, CYS919, ASP1046, and PHE1047 (<a href="#F0005">Figure 5(c)</a>).</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 5.</span></a></div>   <p>Docking of compounds <b>Vd</b>, <b>Ve</b> and the reference ligand <b>Sorafenib</b> into VEGFR active sites. (a) Compounds <b>Vd</b>. (b) Compound <b>Ve</b>. (c) <b>Sorafenib</b>.</p>   </div> </div> </div> <div class="experimental" title="sec"><span class="label" tagx="label" title="label">3.</span><div class="title" tagx="title" title="title">
Experimental</div> <div class="chemistry" title="sec"><span class="label" tagx="label" title="label">3.1.</span><div class="title" tagx="title" title="title">
Chemistry</div> <p>All melting points were uncorrected and measured by Electro thermal IA 9000 series digital melting point apparatus at the Micro-analytical Center, Cairo University (Giza, Egypt). IR spectra had been reported on FT. IR 670-Nicolet spectrophotometer-Nexus (Thermo Scientific, Madison, WT); determination of <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra on a JEOL AS NMR spectrometer (Tokyo, Japan). Mass spectra were measured on Finnigan Mat SSQ 7000 mode EI 70â€‰ev (Thermo Inst. Sys. Inc., Waltham, MA). Thin-layer chromatography was performed using chloroform/methanol (10:1, v/v) on thin-layer chromatographic plates of silica gel 60 F254 (Merck, Kenilworth, NJ), and the spots were observed for a few seconds by exposure to UV lamps at <i>Î»</i>254â€‰nm and used to monitor the reaction time. 1-(4-(Piperazin-1-yl)phenyl)ethan-1-one III was prepared as reported method<a href="#CIT0060"><sup>60</sup></a>.</p> </div> <div class="generalmethodforpreparationof(vaâ€" title="sec"><span class="label" tagx="label" title="label">3.2.</span><div class="title" tagx="title" title="title">
General method for preparation of (Vaâ€"h)</div> <p>A mixture of 4â€²-piperazinoacetophenone <b>III</b> (0.01â€‰mol) and the corresponding aldehyde derivatives <b>IV</b>, namely, 2-cyanobenzaldehyde, 4-cyanobenzaldehyde, 2-flurobenzaldehyde, 3-flurobenzaldehyde, 4-fluro-3-methoxy benzaldehyde, 3-fluroisonicotinaldehyde, 2-hydroxyl-5-nitrobenzaldehyde, and 2-furaldehyde (0.01â€‰mol) was dissolved in 10% alcoholic sodium hydroxide (25â€‰mL) and stirred for 5â€‰h at room temperature. The precipitate was filtered, washed with water, dried, and crystallised from ethanol to give the target compounds <b>Vaâ€"h</b>, respectively.</p> <div class="2-(3-oxo-3-(4-(piperazin-1-yl)phenyl)prop-1-enyl)benzonitrile(va)" title="sec"><span class="label" tagx="label" title="label">3.2.1.</span><div class="title" tagx="title" title="title">
2-(3-Oxo-3-(4-(piperazin-1-yl)phenyl)prop-1-enyl)benzonitrile (Va)</div> <p>Yield 70%, m.p. 150â€‰Â°C. Analysis calculated for C<sub>20</sub>H<sub>19</sub>N<sub>3</sub>O; Calc.: % C, 75.69; H, 6.03; N, 13.24; found: % C, 75.74; H, 6.12; N, 13.10. IR: <i>Ï…</i><sub>max.</sub>/cm<sup>âˆ’m</sup> 3230 (NH), 3020 (Câ€"H aromatic), 2200 (CN), 1700 (C=O), 1580 (C=C). <sup>13</sup>C NMR (DMSO-d<sub>6</sub>): 189, 145, 138, 137,133, 132, 130, 128, 127, 126, 121, 112, 115, 109, 54, 45. <sup>1</sup>H NMR: <i>Î´</i> 2.1 (s, 1H, NH, D<sub>2</sub>O exchangeable), 2.4â€"3.0 (m, 8H, piperazinyl protons), 6.8 (d, 1H, <i>J</i>=Â 15.0â€‰Hz, CHâ•�), and 7.0â€"8.0 (m, 9H, Ar-H, CHâ•�). MS: <i>m/z</i> (% relative intensity)=317 (M<sup>+</sup>, 20%), 215 (100%).</p> </div> <div class="4-(3-oxo-3â€" title="sec"><span class="label" tagx="label" title="label">3.2.2.</span><div class="title" tagx="title" title="title">
4-(3-Oxo-3â€"(4-(piperazin-1-yl)phenyl)prop-1-enyl)benzonitrile (Vb)</div> <p>Yield 75%, m.p. 170â€‰Â°C. Analysis calculated for C<sub>20</sub>H<sub>19</sub>N<sub>3</sub>O; calcd.: % C, 75.69; H, 6.03; N, 13.24; found: % C, 75.72; H, 6.10; N, 13.15. IR: <i>Ï…</i><sub>max.</sub>/cm<sup>âˆ’1</sup> 3240 (NH), 3010 (Câ€"H aromatic), 2210 (CN), 1720 (Câ•�O), 1590 (Câ•�C). <sup>13</sup>C NMR (DMSO-d<sub>6</sub>): 190, 149, 139, 136,133, 132, 128, 127, 121, 118, 112, 111, 55, 46. <sup>1</sup>H NMR: <i>Î´</i> 2.0 (s, 1H, NH, D<sub>2</sub>O exchangeable), 2.5â€"3.1 (m, 8H, piperazinyl protons), 6.8 (d, 1H, <i>J</i>=Â 15.2â€‰Hz, CHâ•�), and 7.3â€"8.1 (m, 9H, Ar-H, CHâ•�). MS: <i>m/z</i> (% relative intensity)=317 (M<sup>+</sup>, 7%), 77 (100%).</p> </div> <div class="3-(2-fluorophenyl)-1-(4-(piperazin-1-yl)phenyl)prop-2-en-1-one(vc)" title="sec"><span class="label" tagx="label" title="label">3.2.3.</span><div class="title" tagx="title" title="title">
3-(2-Fluorophenyl)-1-(4-(piperazin-1-yl)phenyl)prop-2-en-1- one (Vc)</div> <p>Yield 70%, m.p. 176â€‰Â°C. Analysis calculated C<sub>19</sub>H<sub>19</sub>FN<sub>2</sub>O; calcd.: % C, 73.53; H, 6.17; N, 9.03; found: % C, 73.49; H, 6.34; N, 9.12. IR: <i>Ï…</i><sub>max.</sub>/cm<sup>âˆ’1</sup> 3310 (NH), 3000 (Câ€"H aromatic), 1720 (Câ•�O), 1590 (Câ•�C). <sup>13</sup>C NMR (DMSO-d<sub>6</sub>): 192, 161, 145, 138, 132, 130, 129, 127, 125, 123, 121, 115, 112, 55, 46. <sup>1</sup>H NMR: <i>Î´</i> 2.2 (s, 1H, NH, D<sub>2</sub>O exchangeable), 2.7â€"3.3 (m, 8H, piperazinyl protons), 6.7 (d, 1H, <i>J</i>=Â 15.5â€‰Hz, CHâ•�), and 7.1â€"7.9 (m, 9H, Ar-H, CHâ•�). MS: <i>m/z</i> (% relative intensity)=310 (M<sup>+</sup>, 50%), 291 (100%).</p> </div> <div class="3-(3-fluorophenyl)-1-(4-(piperazin-1-yl)phenyl)prop-2-en-1-one(vd)" title="sec"><span class="label" tagx="label" title="label">3.2.4.</span><div class="title" tagx="title" title="title">
3-(3-Fluorophenyl)-1-(4-(piperazin-1-yl)phenyl)prop-2-en-1- one (Vd)</div> <p>Yield 80%, m.p. 200â€‰Â°C. Analysis calculated C<sub>19</sub>H<sub>19</sub>FN<sub>2</sub>O; calcd.: % C, 73.53; H, 6.17; N, 9.03; found: % C, 73.59; H, 6.25; N, 9.10. IR: <i>Ï…</i><sub>max.</sub>/cm<sup>âˆ’1</sup> 3315 (NH), 3010 (Câ€"H aromatic), 1720 (Câ•�O), 1600 (Câ•�C). <sup>13</sup>C NMR (DMSO-d<sub>6</sub>): 189, 162, 145, 137, 136, 133, 131, 127, 124, 122, 115, 114, 113, 55, 47. <sup>1</sup>H NMR: <i>Î´</i> 2.3 (s, 1H, NH, D<sub>2</sub>O exchangeable), 2.6â€"3.1 (m, 8H, piperazinyl protons), 6.8 (d, 1H, <i>J</i>=Â 15.0â€‰Hz, CHâ•�), and 7.2â€"7.7 (m, 9H, Ar-H, CHâ•�). MS: <i>m/z</i> (% relative intensity)=310 (M<sup>+</sup>, 100%).</p> </div> <div class="3-(4-fluoro-3-methoxyphenyl)-1-(4-(piperazin-1-yl)phenyl)prop-2-en-1-one(ve)" title="sec"><span class="label" tagx="label" title="label">3.2.5.</span><div class="title" tagx="title" title="title">
3-(4-Fluoro-3-methoxyphenyl)-1-(4-(piperazin-1-yl)phenyl) prop-2-en-1-one (Ve)</div> <p>Yield 70%, m.p. 180â€‰Â°C. Analysis calculated C<sub>20</sub>H<sub>21</sub>FN<sub>2</sub>O<sub>2</sub>; calcd.: % C, 70.57; H, 6.22; N, 8.23; found: % C, 70.50; H, 6.19; N, 8.27. IR: <i>Ï…</i><sub>max.</sub>/cm<sup>âˆ’1</sup> 3400 (NH), 3050 (Câ€"H aromatic), 1730 (Câ•�O), 1600 (Câ•�C). <sup>13</sup>C NMR (DMSO-d<sub>6</sub>): 190, 151, 149, 145, 137, 132, 131, 127, 123, 121, 117, 113, 112, 57, 50, 45. <sup>1</sup>H NMR: <i>Î´</i> 2.4 (s, 1H, NH, D<sub>2</sub>O exchangeable), 2.8â€"3.3 (m, 8H, piperazinyl protons), 3.80 (s, 3H, OCH<sub>3</sub>), 7.0 (d, 1H, <i>J</i>=Â 15.1â€‰Hz, CHâ•�), and 7.1â€"7.8 (m, 8H, Ar-H, CHâ•�). MS: <i>m/z</i> (% relative intensity)=340 (M<sup>+</sup>, 24%), 85 (100%).</p> </div> <div class="3-(3-fluoropyridin-4-yl)-1-(4-(piperazin-1-yl)phenyl)prop-2-en-1-one(vf)" title="sec"><span class="label" tagx="label" title="label">3.2.6.</span><div class="title" tagx="title" title="title">
3-(3-Fluoropyridin-4-yl)-1-(4-(piperazin-1-yl)phenyl)prop-2- en-1-one (Vf)</div> <p>Yield 75%, m.p. 225â€‰Â°C. Analysis calculated C<sub>18</sub>H<sub>18</sub>FN<sub>3</sub>O; calcd.: % C 69.44; H, 5.83; N, 13.50; found: % C, 69.49; H, 5.95; N, 13.61. IR: <i>Ï…</i><sub>max.</sub>/cm<sup>âˆ’1</sup> 3450 (NH), 3040 (Câ€"H aromatic), 1720 (Câ•�O), 1590 (Câ•�C). <sup>13</sup>C NMR (DMSO-d<sub>6</sub>): 187, 156, 146, 144, 139, 136, 133, 131, 128, 126, 118, 113, 53, 45. <sup>1</sup>H NMR: <i>Î´</i> 2.3 (s, 1H, NH, D<sub>2</sub>O exchangeable), 2.7â€"3.4 (m, 8H, piperazinyl protons), 6.7 (d, 1H, <i>J</i>=Â 15.0â€‰Hz, CHâ•�CH), and 6.9â€"7.8 (m, 8H, Ar-H, CHâ•�). MS: <i>m/z</i> (% relative intensity)=311 (M<sup>+</sup>, 100%).</p> </div> <div class="3-(2-hydroxy-5-nitrophenyl)-1-(4-(piperazin-1-yl)phenyl)prop-2-en-1-one(vg)" title="sec"><span class="label" tagx="label" title="label">3.2.7.</span><div class="title" tagx="title" title="title">
3-(2-Hydroxy-5-nitrophenyl)-1-(4-(piperazin-1-yl)phenyl)prop-2-en-1-one (Vg)</div> <p>Yield 65%, m.p. 185â€‰Â°C. Analysis calculated C<sub>19</sub>H<sub>19</sub>N<sub>3</sub>O<sub>4</sub>; calcd.: % C 64.58; H, 5.42; N, 11.89; found: % C, 64.50; H, 5.37; N, 11.83. IR: <i>Ï…</i><sub>max.</sub>/cm<sup>âˆ’1</sup> 3400 (NH), 3320 (OH), 3010 (Câ€"H aromatic), 1700 (Câ•�O), 1590 (Câ•�C). <sup>13</sup>C NMR (DMSO-d<sub>6</sub>): 195, 163, 141, 140, 139, 131, 129, 126, 125, 120, 119, 116, 112, 54, 45. <sup>1</sup>H NMR: <i>Î´</i> 2.0 (s, 1H, NH, D<sub>2</sub>O exchangeable), 2.4â€"3.1 (m, 8H, piperazinyl protons), 6.6 (d, 1H, <i>J</i>=Â 15.2â€‰Hz, CHâ•�), 7.3â€"7.9 (m, 8H, Ar-H, CHâ•�), and 9.1 (s, 1H, O-H). MS: <i>m/z</i> (% relative intensity)=353 (M<sup>+</sup>, 10%), 290 (100%).</p> </div> <div class="3-(furan-2-yl)-1-(4-(piperazin-1-yl)phenyl)prop-2-en-1-one(vh)" title="sec"><span class="label" tagx="label" title="label">3.2.8.</span><div class="title" tagx="title" title="title">
3-(Furan-2-yl)-1-(4-(piperazin-1-yl)phenyl)prop-2-en-1-one (Vh)</div> <p>Yield 70%, m.p. 190â€‰Â°C. Analysis calculated C<sub>17</sub>H<sub>18</sub>N<sub>2</sub>O<sub>2</sub>; calcd.: % C 72.32; H, 6.43; N, 9.92; found: % C 72.37; H, 6.52; N, 9.90. IR: <i>Ï…</i><sub>max.</sub>/cm<sup>âˆ’1</sup> 3390 (NH), 3030 (Câ€"H aromatic), 1700 (Câ•�O), 1600 (Câ•�C). <sup>13</sup>C NMR (DMSO-d<sub>6</sub>): 188, 151, 140, 137, 130, 127, 126, 120, 114, 112, 110, 50, 45. <sup>1</sup>H NMR: <i>Î´</i> 2.1 (s, 1H, NH, D<sub>2</sub>O exchangeable), 2.9â€"3.5 (m, 8H, piperazinyl protons), 6.7 (d, 1H, <i>J</i>=Â 15.5â€‰Hz, CHâ•�), and 7.0â€"7.8 (m, 8H, Ar-H, CHâ•�). MS: <i>m/z</i> (% relative intensity)=282 (M<sup>+</sup>, 30%), 197 (100%).</p> </div> </div> <div class="generalmethodforthepreparationofviaâ€" title="sec"><span class="label" tagx="label" title="label">3.3.</span><div class="title" tagx="title" title="title">
General method for the preparation of VIaâ€"c</div> <p>A mixture of the chalcone <b>Va</b>, <b>Ve</b>, and <b>Vf</b> (0.006â€‰mol) and hydrazine hydrate (0.006â€‰mol, 98%) in absolute ethanol (30â€‰mL) was heated for 12â€‰h under reflux. The reaction was cooled, the formed precipitate was filtered off and crystallised from ethanol to give compounds <b>VIaâ€"c</b>, respectively.</p> <div class="2-(3-(4-(piperazin-1-yl)phenyl)-4,5-dihydro-1h-pyrazol-5-yl)benzonitrile(via)" title="sec"><span class="label" tagx="label" title="label">3.3.1.</span><div class="title" tagx="title" title="title">
2-(3-(4-(Piperazin-1-yl)phenyl)-4,5-dihydro-1H-pyrazol-5-yl)benzonitrile (VIa)</div> <p>Yield 64%, m.p. 165â€‰Â°C. Analysis calculated C<sub>20</sub>H<sub>21</sub>N<sub>5</sub>; calcd.: % C 72.48; H, 6.39; N, 21.13; found: % C 72.54; H, 6.42; N, 21.10. IR: <i>Ï…</i><sub>max.</sub>/cm<sup>âˆ’1</sup> 3320 (NH), 3030 (Câ€"H aromatic), 2220 (CN), 1600 (Câ•�C). <sup>13</sup>C NMR (DMSO-d<sub>6</sub>): 151, 146, 134, 133, 131, 129, 128, 127, 125, 115, 112, 111, 54, 47, 45, 42. <sup>1</sup>H NMR: <i>Î´</i> 2.1 (s, 1H, NH, D<sub>2</sub>O exchangeable), 2.4â€"2.9 (m, 8H, piperazinyl protons), 3.3 (dd, 1H, <i>J</i>=Â 11.4, 5.1â€‰Hz, pyrazoline), 3.4 (dd, 1H, <i>J</i>=Â 11.3, 6.1â€‰Hz, pyrazoline), 5.0 (dd, 1H, <i>J</i>â€‰=â€‰11.0, 5.5â€‰Hz, pyrazoline), 7.0â€"7.7 (m, 8H, Ar-H), and 9.0 (s, NH, D<sub>2</sub>O exchangeable). MS: <i>m/z</i> (% relative intensity)=331 (M<sup>+</sup>, 14%), 77 (100%).</p> </div> <div class="1-(4-(5-(4-fluoro-3-methoxyphenyl)-4,5-dihydro-1h-pyrazol-3-yl)phenyl)piperazine(vib)" title="sec"><span class="label" tagx="label" title="label">3.3.2.</span><div class="title" tagx="title" title="title">
1-(4-(5-(4-Fluoro-3-methoxyphenyl)-4,5-dihydro-1H-pyrazol- 3-yl)phenyl) piperazine (VIb)</div> <p>Yield 70%, m.p. 195â€‰Â°C. Analysis calculated C<sub>20</sub>H<sub>23</sub>FN<sub>4</sub>O; calcd.: % C 67.78; H, 6.54; N, 15.81; found: % C 67.70; H, 6.59; N, 15.74. IR: <i>Ï…</i><sub>max.</sub>/cm<sup>âˆ’1</sup> 3400 (NH), 3040 (Câ€"H aromatic), 1590 (Câ•�C). <sup>13</sup>C NMR (DMSO-d<sub>6</sub>): 152, 150, 148, 140, 133, 130, 125, 120, 116, 112, 111, 56, 52, 50, 46, 43. <sup>1</sup>H NMR: <i>Î´</i> 2.3 (s, 1H, NH, D<sub>2</sub>O exchangeable), 2.6â€"3.0 (m, 8H, piperazinyl protons), 3.2 (dd, 1H, <i>J=</i>Â 11.3, 6.1â€‰Hz, pyrazoline), 3.3 (dd, 1H, <i>J</i>=Â 11.7, 5.9â€‰Hz, pyrazoline), 3.8 (s, 3H, OCH<sub>3</sub>), 5.1 (dd, 1H, <i>J</i>=Â 11.9, 6.1â€‰Hz, pyrazoline), 6.9â€"7.5 (m, 7H, Ar-H), and 8.5 (s, NH, D<sub>2</sub>O exchangeable). MS: <i>m/z</i> (% relative intensity)=354 (M<sup>+</sup>, 100%).</p> </div> <div class="1-(4-(5-(3-fluoropyridin-4-yl)-4,5-dihydro-1h-pyrazol-3-yl)phenyl)piperazine(vic)" title="sec"><span class="label" tagx="label" title="label">3.3.3.</span><div class="title" tagx="title" title="title">
1-(4-(5-(3-Fluoropyridin-4-yl)-4,5-dihydro-1H-pyrazol-3-yl) phenyl) piperazine (VIc)</div> <p>Yield 70%, m.p. 135â€‰Â°C. Analysis calculated C<sub>18</sub>H<sub>20</sub>FN<sub>5</sub>; calcd.: % C 66.44; H, 6.20; N, 21.52; found: % C 66.49; H, 6.25; N, 21.548 IR: <i>Ï…</i><sub>max.</sub>/cm<sup>âˆ’1</sup> 3390 (NH), 3020 (Câ€"H aromatic), 1595 (Câ•�C). <sup>13</sup>C NMR (DMSO-d<sub>6</sub>): 152, 150, 147, 139, 138, 133, 130, 125, 124, 111, 54, 47, 45, 44. <sup>1</sup>H NMR: <i>Î´</i> 2.3 (s, 1H, NH, D<sub>2</sub>O exchangeable), 2.7â€"3.2 (m, 8H, piperazinyl protons), 3.4 (dd, 1H, <i>J</i>â€‰=â€‰11.2, 5.0â€‰Hz, pyrazoline), 3.6 (dd, 1H, <i>J</i>=Â 11.6, 5.9â€‰Hz, pyrazoline), 5.2 (dd, 1H, <i>J</i>=Â 12.0, 5.7â€‰Hz, pyrazoline), 7.0â€"7.9 (m, 7H, Ar-H), and 8.8 (s, NH, D<sub>2</sub>O exchangeable). MS: <i>m/z</i> (% relative intensity)=325 (M<sup>+</sup>, 19%), 229 (100%).</p> </div> </div> <div class="invitrocytotoxicity" title="sec"><span class="label" tagx="label" title="label">3.4.</span><div class="title" tagx="title" title="title"><i>In vitro</i> cytotoxicity</div> <p><i>In vitro</i> cytotoxicity was performed in NCI according to reported method<a href="#CIT0061"><sup>61</sup></a>.</p> </div> <div class="vegfr-2inhibitionassay" title="sec"><span class="label" tagx="label" title="label">3.5.</span><div class="title" tagx="title" title="title">
VEGFR-2 inhibition assay</div> <p>IC<sub>50</sub>s of <b>Vd</b>, <b>Ve</b>, <b>Vf</b>, <b>VIa</b>, <b>VIb</b>, and <b>VIc</b> compounds were evaluated <i>inÂ vitro</i> using colorimetric assay of human VEGFR-2 ELISA (enzyme-linked immunosorbent assay) kits (HTScan<sup>Â®</sup> VEGF Receptor 2 Kinase Assay Kit). It includes active VEGFR-2 kinase (a biotinylated peptide substrate and a phospho-tyrosine antibody) for detection of the phosphorylated form of the substrate peptide. On a 96-well plate, a particular VEGFR-2 antibody was seeded and 100â€‰ÂµL of the normal solution or compound tested was applied, incubated at room temperature for 2.5â€‰h and washed.</p> <p>Then, 100â€‰ÂµL of the prepared biotin antibody was added, incubated for an additional 1â€‰h at room temperature and washed. Following, 100â€‰ÂµL of streptavidin solution was added at room temperature, incubated for 45â€‰min and then, 100â€‰ÂµL of TMB substrate solution was applied and incubated at room temperature for 30â€‰min. Finally, 50â€‰ÂµL stop solution was added and the absorption was measured at 450â€‰nm instantly. The standard curve, the <i>X</i>-axis concentrations, and the <i>Y</i>-axis absorbance were drawn.</p> </div> <div class="cellcycleanalysis" title="sec"><span class="label" tagx="label" title="label">3.6.</span><div class="title" tagx="title" title="title">
Cell cycle analysis</div> <p>HCT-116 cells were seeded at concentrations of 1â€‰Ã—â€‰10<sup>5</sup> cells per well in a six-well plate, then incubated for 24â€‰h. The cells were treated for 24â€‰h with vehicles (0.1% DMSO) or 10â€‰ÂµM of <b>Vd</b> or <b>Ve</b> compounds. Using ice-cold, 70% ethanol at 4â€‰Â°C, cells were harvested and fixed for 12â€‰h after that. Ethanol removal and cold PBS washing of the cells were done. Then incubated in 0.5â€‰mL of PBS containing 1â€‰mg/mL Ranse for 30â€‰min at 37â€‰Â°C. In the dark, the cells were stained with PI for 30â€‰min. Flow cytometer was then used to detect contents of DNA<a href="#CIT0062"><sup>62</sup></a>.</p> </div> <div class="annexinv-fitcapoptosisassay" title="sec"><span class="label" tagx="label" title="label">3.7.</span><div class="title" tagx="title" title="title">
Annexin V-FITC apoptosis assay</div> <p>For this study, annexin V-FITC/PI apoptosis detection kit was used; HCT-116 cells were stained with annexin V fluorescein isothiocyanate (FITC) and PI counter-stained. 1â€‰Ã—â€‰10<sup>5</sup> HCT-116 cells were 48â€‰h incubated with compound <b>Vd</b> or <b>Ve</b>, trypsinised, washed with phosphate-buffered saline (PBS), stained in the dark at 37â€‰Â°C for 15â€‰min. Then, analysed with a cytometer of FACS calibre flow<a href="#CIT0063"><sup>63</sup></a>.</p> </div> <div class="moleculardocking" title="sec"><span class="label" tagx="label" title="label">3.8.</span><div class="title" tagx="title" title="title">
Molecular docking</div> <p>Molecular docking simulation studies were performed using molecular operating environment (MOE<sup>Â®</sup>) version 2015.10. The vascular endothelial growth factor receptor (VEGFR) (PDB 4ASD) was used as a receptor for the docking study and <b>Sorafenib</b> as a reference drug.</p> <div class="targetcompoundsoptimisation" title="sec"><span class="label" tagx="label" title="label">3.8.1.</span><div class="title" tagx="title" title="title">
Target compounds optimisation</div> <p>Using the MOE program builder interface, the tested compounds <b>Vd</b>, <b>Ve</b>, <b>Vf</b>, <b>VIa</b>, <b>VIb</b>, and <b>VIc</b> were created into a 3D model. The target structures were checked by 2D depiction and formal charges on atoms, and then a conformational search was conducted for the target compounds. All conformers were subjected to energy minimisation done with MOE until an RMSD gradient of 0.01â€‰kcal/mol and an RMS distance of 0.1Â Ã… with MMFF94X were automatically measured as a force-field and the partial charges. The database of target compounds was then saved as MDB file for use in the calculations for molecular docking.</p> </div> <div class="optimisationofvegfractivesite" title="sec"><span class="label" tagx="label" title="label">3.8.2.</span><div class="title" tagx="title" title="title">
Optimisation of VEGFR active site</div> <p>The VEGFR has been prepared for docking experiments by adding hydrogen atoms and their standard geometry. The atom's connections and types were checked with automatic correction for any errors that existed. Selection of the receptor and its potential atoms has been fixed. MOE Alpha Site Finder used all default items to search for the active site in the receptor structure, and then dummy atoms were created from the alpha spheres obtained.</p> </div> <div class="dockingofthetargetcompoundstothevegfractivesites" title="sec"><span class="label" tagx="label" title="label">3.8.3.</span><div class="title" tagx="title" title="title">
Docking of the target compounds to the VEGFR active sites</div> <p>Docking of the tested compounds' conformational database was performed using MOE-Dock software. To ensure a reasonable docking accuracy and to determine the effect of the water molecules, the co-crystallised ligand in the VEGFR (PDB 4ASD) was docked to its corresponding protein (in the absence and in the presence of water) and the RMSD values were determined between the co-crystallised ligand and docked pose. The success rates obtained were highly excellent where the active site of the VEGFR was calculated from the binding of co-crystallised ligand and saved as MOE file. The active site file of the VEGFR was then loaded, and the docking tool was used. The program specifications have been adjusted to the dummy atoms as docking site, triangle matcher as placement methodology, London dG as scoring methodology that have been adjusted to its default values. The MDB file of the ligands to be docked (<b>Sorafenib</b> and target compounds) was loaded, and calculations for docking were run automatically. The poses obtained were studied and the poses which had the best ligandâ€"receptor interactions were selected and stored for calculating energy.</p> </div> </div> </div> <div class="conclusions" title="sec"><span class="label" tagx="label" title="label">4.</span><div class="title" tagx="title" title="title">
Conclusions</div> <p>In summary, novel piperazineâ€"chalcone hybrids and related pyrazoline analogues were synthesised and six of them were selected at a single dose concentration (10<sup>âˆ’1</sup>Â M) by NCI (Bethesda, MD) to test their <i>inÂ vitro</i> anticancer activity against full 60 lines of human cancer cells. VEGFR-2 enzyme inhibitory assay was performed to investigate the mechanism of anticancer activity of the tested compounds. While, all tested compounds demonstrate good inhibitory activity against VEGFR-2, the most active compounds were <b>Vd</b> and <b>Ve</b> that have been shown to be able to cause cell cycle arrest during the G2/M process and inducing apoptosis in HCT-116 cells. The present research has led to the discovery of new cytotoxic compounds that target the VEGFR-2. Furthermore, a molecular docking study of selected compounds was carried out and confirmed that compounds <b>Vd</b> and <b>Ve</b> exhibited a direct interaction with the VEGFR.</p> </div> <div class="supplementary-material" title="supplementary-material"> <div class="title" tagx="title" title="title">
Supplementary Material</div> <div class="local-data" title="local-data">  <div class="title" tagx="title" title="title">
Supplemental Material</div>  <div class="media" title="media"><a href="IENZ_A_1861606_SM7084.pdf">LINK</a> <p>Click here for additional data file.</p>  </div> </div> </div> </div> <div class="back" title="back"> <div class="ack" title="ack"> <div class="title" tagx="title" title="title">
Acknowledgements</div> <p>The authors are thankful to National Cancer Institute (NCI) of the United States for performing anticancer evaluation over the 60-cancer cell line.</p> </div> <div class="COI-statement" title="COI-statement"> <div class="title" tagx="title" title="title">
Disclosure statement</div> <p>No potential conflict of interest was reported by the author(s).</p> </div> <div class="references">
References</div> <div tag="ref-list"> <ul> <div class="title" tagx="title" title="title">
References</div> <li tag="ref"><a name="CIT0001" /><span class="label" tagx="label" title="label">1</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Varmus</span><span class="given-names" tagx="given-names" title="given-names">H.</span></span></span><span class="mixed-article-title" title="mixed-article-title">The new era in cancer research</span>. <span class="source" tagx="source" title="source">Science</span><span class="year" tagx="year" title="year">2006</span>;<span class="volume" tagx="volume" title="volume">312</span>:<span class="fpage" tagx="fpage" title="fpage">1162</span>â€"<span class="lpage" tagx="lpage" title="lpage">5</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16728627">16728627</a></span></span></li> <li tag="ref"><a name="CIT0002" /><span class="label" tagx="label" title="label">2</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gibbs</span><span class="given-names" tagx="given-names" title="given-names">JB.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Mechanism-based target identification and drug discovery in cancer research</span>. <span class="source" tagx="source" title="source">Science</span><span class="year" tagx="year" title="year">2000</span>;<span class="volume" tagx="volume" title="volume">287</span>:<span class="fpage" tagx="fpage" title="fpage">1969</span>â€"<span class="lpage" tagx="lpage" title="lpage">73</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10720316">10720316</a></span></span></li> <li tag="ref"><a name="CIT0003" /><span class="label" tagx="label" title="label">3</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kerru</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Singh</span><span class="given-names" tagx="given-names" title="given-names">P</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Koorbanally</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Recent advances (2015â€"2016) in anticancer hybrids</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2017</span>;<span class="volume" tagx="volume" title="volume">142</span>:<span class="fpage" tagx="fpage" title="fpage">179</span>â€"<span class="lpage" tagx="lpage" title="lpage">212</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28760313">28760313</a></span></span></li> <li tag="ref"><a name="CIT0004" /><span class="label" tagx="label" title="label">4</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gerber</span><span class="given-names" tagx="given-names" title="given-names">DE.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Targeted therapies: a new generation of cancer treatments</span>. <span class="source" tagx="source" title="source">Am Fam Phys</span><span class="year" tagx="year" title="year">2008</span>;<span class="volume" tagx="volume" title="volume">77</span>:<span class="fpage" tagx="fpage" title="fpage">311</span>â€"<span class="lpage" tagx="lpage" title="lpage">9</span>.</span></li> <li tag="ref"><a name="CIT0005" /><span class="label" tagx="label" title="label">5</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kerbel</span><span class="given-names" tagx="given-names" title="given-names">RS.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Tumor angiogenesis: past, present and the near future</span>. <span class="source" tagx="source" title="source">Carcinogenesis</span><span class="year" tagx="year" title="year">2000</span>;<span class="volume" tagx="volume" title="volume">21</span>:<span class="fpage" tagx="fpage" title="fpage">505</span>â€"<span class="lpage" tagx="lpage" title="lpage">15</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10688871">10688871</a></span></span></li> <li tag="ref"><a name="CIT0006" /><span class="label" tagx="label" title="label">6</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Polverini</span><span class="given-names" tagx="given-names" title="given-names">PJ.</span></span></span><span class="mixed-article-title" title="mixed-article-title">The pathophysiology of angiogenesis</span>. <span class="source" tagx="source" title="source">Crit Rev Oral Biol Med</span><span class="year" tagx="year" title="year">1995</span>;<span class="volume" tagx="volume" title="volume">6</span>:<span class="fpage" tagx="fpage" title="fpage">230</span>â€"<span class="lpage" tagx="lpage" title="lpage">47</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8785263">8785263</a></span></span></li> <li tag="ref"><a name="CIT0007" /><span class="label" tagx="label" title="label">7</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Baeriswyl</span><span class="given-names" tagx="given-names" title="given-names">V</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Christofori</span><span class="given-names" tagx="given-names" title="given-names">G.</span></span></span><span class="mixed-article-title" title="mixed-article-title">The angiogenic switch in carcinogenesis</span>. <span class="source" tagx="source" title="source">Semin Cancer Biol</span><span class="year" tagx="year" title="year">2009</span>;<span class="volume" tagx="volume" title="volume">19</span>:<span class="fpage" tagx="fpage" title="fpage">329</span>â€"<span class="lpage" tagx="lpage" title="lpage">37</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19482086">19482086</a></span></span></li> <li tag="ref"><a name="CIT0008" /><span class="label" tagx="label" title="label">8</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Fidler</span><span class="given-names" tagx="given-names" title="given-names">IJ.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Angiogenesis and cancer metastasis</span>. <span class="source" tagx="source" title="source">Cancer J</span><span class="year" tagx="year" title="year">2000</span>;<span class="volume" tagx="volume" title="volume">6</span>:<span class="fpage" tagx="fpage" title="fpage">S134</span>â€"<span class="lpage" tagx="lpage" title="lpage">S41</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10803828">10803828</a></span></span></li> <li tag="ref"><a name="CIT0009" /><span class="label" tagx="label" title="label">9</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Shawver</span><span class="given-names" tagx="given-names" title="given-names">LK</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lipson</span><span class="given-names" tagx="given-names" title="given-names">KE</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Fong</span><span class="given-names" tagx="given-names" title="given-names">TAT</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Receptor tyrosine kinases as targets for inhibition of angiogenesis</span>. <span class="source" tagx="source" title="source">Drug Discov Today</span><span class="year" tagx="year" title="year">1997</span>;<span class="volume" tagx="volume" title="volume">2</span>:<span class="fpage" tagx="fpage" title="fpage">50</span>â€"<span class="lpage" tagx="lpage" title="lpage">63</span>.</span></li> <li tag="ref"><a name="CIT0010" /><span class="label" tagx="label" title="label">10</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Traxler</span><span class="given-names" tagx="given-names" title="given-names">P.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Tyrosine kinases as targets in cancer therapy â€" successes and failures</span>. <span class="source" tagx="source" title="source">Expert Opin Ther Targets</span><span class="year" tagx="year" title="year">2003</span>;<span class="volume" tagx="volume" title="volume">7</span>:<span class="fpage" tagx="fpage" title="fpage">215</span>â€"<span class="lpage" tagx="lpage" title="lpage">34</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12667099">12667099</a></span></span></li> <li tag="ref"><a name="CIT0011" /><span class="label" tagx="label" title="label">11</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abhinand</span><span class="given-names" tagx="given-names" title="given-names">CS</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Raju</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Soumya</span><span class="given-names" tagx="given-names" title="given-names">SJ</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">VEGF-A/VEGFR2 signaling network in endothelial cells relevant to angiogenesis</span>. <span class="source" tagx="source" title="source">J Cell Commun Signal</span><span class="year" tagx="year" title="year">2016</span>;<span class="volume" tagx="volume" title="volume">10</span>:<span class="fpage" tagx="fpage" title="fpage">347</span>â€"<span class="lpage" tagx="lpage" title="lpage">54</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27619687">27619687</a></span></span></li> <li tag="ref"><a name="CIT0012" /><span class="label" tagx="label" title="label">12</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hoeben</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Landuyt</span><span class="given-names" tagx="given-names" title="given-names">B</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Highley</span><span class="given-names" tagx="given-names" title="given-names">MS</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Vascular endothelial growth factor and angiogenesis</span>. <span class="source" tagx="source" title="source">Pharmacol Rev</span><span class="year" tagx="year" title="year">2004</span>;<span class="volume" tagx="volume" title="volume">56</span>:<span class="fpage" tagx="fpage" title="fpage">549</span>â€"<span class="lpage" tagx="lpage" title="lpage">80</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15602010">15602010</a></span></span></li> <li tag="ref"><a name="CIT0013" /><span class="label" tagx="label" title="label">13</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ferrara</span><span class="given-names" tagx="given-names" title="given-names">N.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Vascular endothelial growth factor: basic science and clinical progress</span>. <span class="source" tagx="source" title="source">Endocr Rev</span><span class="year" tagx="year" title="year">2004</span>;<span class="volume" tagx="volume" title="volume">25</span>:<span class="fpage" tagx="fpage" title="fpage">581</span>â€"<span class="lpage" tagx="lpage" title="lpage">611</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15294883">15294883</a></span></span></li> <li tag="ref"><a name="CIT0014" /><span class="label" tagx="label" title="label">14</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lohela</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bry</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tammela</span><span class="given-names" tagx="given-names" title="given-names">T</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">VEGFs and receptors involved in angiogenesis versus lymphangiogenesis</span>. <span class="source" tagx="source" title="source">Curr Opin Cell Biol</span><span class="year" tagx="year" title="year">2009</span>;<span class="volume" tagx="volume" title="volume">21</span>:<span class="fpage" tagx="fpage" title="fpage">154</span>â€"<span class="lpage" tagx="lpage" title="lpage">65</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19230644">19230644</a></span></span></li> <li tag="ref"><a name="CIT0015" /><span class="label" tagx="label" title="label">15</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Shibuya</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies</span>. <span class="source" tagx="source" title="source">Genes Cancer</span><span class="year" tagx="year" title="year">2011</span>;<span class="volume" tagx="volume" title="volume">2</span>:<span class="fpage" tagx="fpage" title="fpage">1097</span>â€"<span class="lpage" tagx="lpage" title="lpage">105</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22866201">22866201</a></span></span></li> <li tag="ref"><a name="CIT0016" /><span class="label" tagx="label" title="label">16</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Daniel</span><span class="given-names" tagx="given-names" title="given-names">JE</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">La</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Julie</span><span class="given-names" tagx="given-names" title="given-names">B</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis</span>. <span class="source" tagx="source" title="source">J Med Chem</span><span class="year" tagx="year" title="year">2008</span>;<span class="volume" tagx="volume" title="volume">51</span>:<span class="fpage" tagx="fpage" title="fpage">1695</span>â€"<span class="lpage" tagx="lpage" title="lpage">705</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18311900">18311900</a></span></span></li> <li tag="ref"><a name="CIT0017" /><span class="label" tagx="label" title="label">17</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Machado</span><span class="given-names" tagx="given-names" title="given-names">VA</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Peixoto</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Costa</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis, antiangiogenesis evaluation and molecular docking studies of 1-aryl-3-[(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas: discovery of a new substitution pattern for type II VEGFR-2 Tyr kinase inhibitors</span>. <span class="source" tagx="source" title="source">Bioorg Med Chem</span><span class="year" tagx="year" title="year">2015</span>;<span class="volume" tagx="volume" title="volume">23</span>:<span class="fpage" tagx="fpage" title="fpage">6497</span>â€"<span class="lpage" tagx="lpage" title="lpage">509</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26344591">26344591</a></span></span></li> <li tag="ref"><a name="CIT0018" /><span class="label" tagx="label" title="label">18</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rajagopalan</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Balasubramanian</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ramaswamy</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Pharmacophore based 3D-QSAR modeling and free energy analysis of VEGFR-2 inhibitors</span>. <span class="source" tagx="source" title="source">J Enzyme Inhib Med Chem</span><span class="year" tagx="year" title="year">2013</span>;<span class="volume" tagx="volume" title="volume">28</span>:<span class="fpage" tagx="fpage" title="fpage">1236</span>â€"<span class="lpage" tagx="lpage" title="lpage">46</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23061928">23061928</a></span></span></li> <li tag="ref"><a name="CIT0019" /><span class="label" tagx="label" title="label">19</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Elsayed</span><span class="given-names" tagx="given-names" title="given-names">NMY</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Serya</span><span class="given-names" tagx="given-names" title="given-names">RAT</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tolba</span><span class="given-names" tagx="given-names" title="given-names">MF</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Design, synthesis, biological evaluation and dynamics simulation of indazole derivatives with antiangiogenic and antiproliferative anticancer activity</span>. <span class="source" tagx="source" title="source">Bioorg Chem</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">82</span>:<span class="fpage" tagx="fpage" title="fpage">340</span>â€"<span class="lpage" tagx="lpage" title="lpage">59</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30428414">30428414</a></span></span></li> <li tag="ref"><a name="CIT0020" /><span class="label" tagx="label" title="label">20</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Muresan-Pop</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chereches</span><span class="given-names" tagx="given-names" title="given-names">G</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Borodi</span><span class="given-names" tagx="given-names" title="given-names">G</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Structural characterization of 5-fluorouracil &amp;amp; piperazine new solid forms and evaluation of their antitumor activity</span>. <span class="source" tagx="source" title="source">J Mol Struct</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">1207</span>:<span class="fpage" tagx="fpage" title="fpage">127842</span>.</span></li> <li tag="ref"><a name="CIT0021" /><span class="label" tagx="label" title="label">21</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mao</span><span class="given-names" tagx="given-names" title="given-names">ZW</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zheng</span><span class="given-names" tagx="given-names" title="given-names">X</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lin</span><span class="given-names" tagx="given-names" title="given-names">YP</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Design, synthesis and anticancer activity of novel hybrid compounds between benzofuran and N-aryl piperazine</span>. <span class="source" tagx="source" title="source">Bioorg Med Chem Lett</span><span class="year" tagx="year" title="year">2016</span>;<span class="volume" tagx="volume" title="volume">26</span>:<span class="fpage" tagx="fpage" title="fpage">3421</span>â€"<span class="lpage" tagx="lpage" title="lpage">4</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27371110">27371110</a></span></span></li> <li tag="ref"><a name="CIT0022" /><span class="label" tagx="label" title="label">22</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Patel</span><span class="given-names" tagx="given-names" title="given-names">RV</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mistry</span><span class="given-names" tagx="given-names" title="given-names">B</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Syed</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Chrysinâ€"piperazine conjugates as antioxidant and anticancer agents</span>. <span class="source" tagx="source" title="source">Eur J Pharm Sci</span><span class="year" tagx="year" title="year">2016</span>;<span class="volume" tagx="volume" title="volume">88</span>:<span class="fpage" tagx="fpage" title="fpage">166</span>â€"<span class="lpage" tagx="lpage" title="lpage">77</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26924226">26924226</a></span></span></li> <li tag="ref"><a name="CIT0023" /><span class="label" tagx="label" title="label">23</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mehtap</span><span class="given-names" tagx="given-names" title="given-names">T</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Halise</span><span class="given-names" tagx="given-names" title="given-names">IG</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kenjiro</span><span class="given-names" tagx="given-names" title="given-names">B</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis and biological evaluation of some new mono Mannich bases with piperazines as possible anticancer agents and carbonic anhydrase inhibitors</span>. <span class="source" tagx="source" title="source">Bioorg Chem</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">90</span>:<span class="fpage" tagx="fpage" title="fpage">103095</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31288135">31288135</a></span></span></li> <li tag="ref"><a name="CIT0024" /><span class="label" tagx="label" title="label">24</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gokhan-Kelekci</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yabanoglu</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kupeli</span><span class="given-names" tagx="given-names" title="given-names">E</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">A new therapeutic approach in Alzheimer disease: some novel pyrazole derivatives as dual MAO-B inhibitors and anti-inflammatory analgesics</span>. <span class="source" tagx="source" title="source">Bioorg Med Chem</span><span class="year" tagx="year" title="year">2007</span>;<span class="volume" tagx="volume" title="volume">15</span>:<span class="fpage" tagx="fpage" title="fpage">5775</span>â€"<span class="lpage" tagx="lpage" title="lpage">86</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17611112">17611112</a></span></span></li> <li tag="ref"><a name="CIT0025" /><span class="label" tagx="label" title="label">25</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abdel-Aziz</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abuo-Rahma</span><span class="given-names" tagx="given-names" title="given-names">GA</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hassan</span><span class="given-names" tagx="given-names" title="given-names">AA.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis of novel pyrazole derivatives and evaluation of their antidepressant and anticonvulsant activities</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2009</span>;<span class="volume" tagx="volume" title="volume">44</span>:<span class="fpage" tagx="fpage" title="fpage">3480</span>â€"<span class="lpage" tagx="lpage" title="lpage">7</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19268406">19268406</a></span></span></li> <li tag="ref"><a name="CIT0026" /><span class="label" tagx="label" title="label">26</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kaushik</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Khan</span><span class="given-names" tagx="given-names" title="given-names">SA</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chawla</span><span class="given-names" tagx="given-names" title="given-names">G</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Nâ€²-[(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene] 2/4-substituted hydrazides: synthesis and anticonvulsant activity</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2010</span>;<span class="volume" tagx="volume" title="volume">45</span>:<span class="fpage" tagx="fpage" title="fpage">3943</span>â€"<span class="lpage" tagx="lpage" title="lpage">9</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20573423">20573423</a></span></span></li> <li tag="ref"><a name="CIT0027" /><span class="label" tagx="label" title="label">27</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Khunt</span><span class="given-names" tagx="given-names" title="given-names">RC</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Khedkar</span><span class="given-names" tagx="given-names" title="given-names">VM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chawda</span><span class="given-names" tagx="given-names" title="given-names">RS</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis, antitubercular evaluation and 3D-QSAR study of N-phenyl-3-(4-fluorophenyl)-4-substituted pyrazole derivatives</span>. <span class="source" tagx="source" title="source">Bioorg Med Chem Lett</span><span class="year" tagx="year" title="year">2012</span>;<span class="volume" tagx="volume" title="volume">22</span>:<span class="fpage" tagx="fpage" title="fpage">666</span>â€"<span class="lpage" tagx="lpage" title="lpage">78</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22104148">22104148</a></span></span></li> <li tag="ref"><a name="CIT0028" /><span class="label" tagx="label" title="label">28</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Pathak</span><span class="given-names" tagx="given-names" title="given-names">RB</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chovatia</span><span class="given-names" tagx="given-names" title="given-names">PT</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Parekh</span><span class="given-names" tagx="given-names" title="given-names">HH.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis, antitubercular and antimicrobial evaluation of 3-(4-chlorophenyl)-4-substituted pyrazole derivatives</span>. <span class="source" tagx="source" title="source">Bioorg Med Chem Lett</span><span class="year" tagx="year" title="year">2012</span>;<span class="volume" tagx="volume" title="volume">22</span>:<span class="fpage" tagx="fpage" title="fpage">5129</span>â€"<span class="lpage" tagx="lpage" title="lpage">33</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22695129">22695129</a></span></span></li> <li tag="ref"><a name="CIT0029" /><span class="label" tagx="label" title="label">29</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Malladi</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Isloor</span><span class="given-names" tagx="given-names" title="given-names">AM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Peethambar</span><span class="given-names" tagx="given-names" title="given-names">SK</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis and antimicrobial activity of some new pyrazole containing cyanopyridone derivatives</span>. <span class="source" tagx="source" title="source">Der Pharm Chem</span><span class="year" tagx="year" title="year">2012</span>;<span class="volume" tagx="volume" title="volume">4</span>:<span class="fpage" tagx="fpage" title="fpage">43</span>â€"<span class="lpage" tagx="lpage" title="lpage">52</span>.</span></li> <li tag="ref"><a name="CIT0030" /><span class="label" tagx="label" title="label">30</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Puthran</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Poojary</span><span class="given-names" tagx="given-names" title="given-names">B</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Purushotham</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis of novel Schiff bases using 2-amino-5-(3-fluoro-4-methoxyphenyl)thiophene-3-carbonitrile and 1,3-disubstituted pyrazole-4-carboxaldehydes derivatives and their antimicrobial activity</span>. <span class="source" tagx="source" title="source">Heliyon</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">5</span>:<span class="fpage" tagx="fpage" title="fpage">e02233</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31485504">31485504</a></span></span></li> <li tag="ref"><a name="CIT0031" /><span class="label" tagx="label" title="label">31</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Vijesh</span><span class="given-names" tagx="given-names" title="given-names">AM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Isloor</span><span class="given-names" tagx="given-names" title="given-names">AM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Shetty</span><span class="given-names" tagx="given-names" title="given-names">P</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">New pyrazole derivatives containing 1,2,4-triazoles and benzoxazoles as potent antimicrobial and analgesic agents</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2013</span>;<span class="volume" tagx="volume" title="volume">62</span>:<span class="fpage" tagx="fpage" title="fpage">410</span>â€"<span class="lpage" tagx="lpage" title="lpage">5</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23385092">23385092</a></span></span></li> <li tag="ref"><a name="CIT0032" /><span class="label" tagx="label" title="label">32</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zabiulla</span><span class="given-names" tagx="given-names" title="given-names">GA</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mohammed</span><span class="given-names" tagx="given-names" title="given-names">YHE</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Design, synthesis and molecular docking of benzophenone conjugated with oxadiazole sulphur bridge pyrazole pharmacophores as anti-inflammatory and analgesic agents</span>. <span class="source" tagx="source" title="source">Bioorg Chem</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">92</span>:<span class="fpage" tagx="fpage" title="fpage">103220</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31493708">31493708</a></span></span></li> <li tag="ref"><a name="CIT0033" /><span class="label" tagx="label" title="label">33</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Koca</span><span class="given-names" tagx="given-names" title="given-names">Ä°</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ã–zgÃ¼r</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">CoÅŸkun</span><span class="given-names" tagx="given-names" title="given-names">KA</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis and anticancer activity of acyl thioureas bearing pyrazole moiety</span>. <span class="source" tagx="source" title="source">Bioorg Med Chem</span><span class="year" tagx="year" title="year">2013</span>;<span class="volume" tagx="volume" title="volume">21</span>:<span class="fpage" tagx="fpage" title="fpage">3859</span>â€"<span class="lpage" tagx="lpage" title="lpage">65</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23664495">23664495</a></span></span></li> <li tag="ref"><a name="CIT0034" /><span class="label" tagx="label" title="label">34</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abdellatif</span><span class="given-names" tagx="given-names" title="given-names">KR</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abdelall</span><span class="given-names" tagx="given-names" title="given-names">EK</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abdelgawad</span><span class="given-names" tagx="given-names" title="given-names">MA</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis and anticancer activity of some new pyrazolo[3,4-d]pyrimidin-4-one derivatives</span>. <span class="source" tagx="source" title="source">Molecules</span><span class="year" tagx="year" title="year">2014</span>;<span class="volume" tagx="volume" title="volume">19</span>:<span class="fpage" tagx="fpage" title="fpage">3297</span>â€"<span class="lpage" tagx="lpage" title="lpage">309</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24647032">24647032</a></span></span></li> <li tag="ref"><a name="CIT0035" /><span class="label" tagx="label" title="label">35</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Dawood</span><span class="given-names" tagx="given-names" title="given-names">KM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Eldebss</span><span class="given-names" tagx="given-names" title="given-names">TMA</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">El-Zahabi</span><span class="given-names" tagx="given-names" title="given-names">HSA</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis of some new pyrazole-based 1,3-thiazoles and 1,3,4-thiadiazoles as anticancer agents</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2013</span>;<span class="volume" tagx="volume" title="volume">70</span>:<span class="fpage" tagx="fpage" title="fpage">740</span>â€"<span class="lpage" tagx="lpage" title="lpage">9</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24231309">24231309</a></span></span></li> <li tag="ref"><a name="CIT0036" /><span class="label" tagx="label" title="label">36</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tu</span><span class="given-names" tagx="given-names" title="given-names">CH</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lin</span><span class="given-names" tagx="given-names" title="given-names">WH</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Peng</span><span class="given-names" tagx="given-names" title="given-names">YH</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Pyrazolylamine derivatives reveal the conformational switching between type I and type II binding modes of anaplastic lymphoma kinase (ALK)</span>. <span class="source" tagx="source" title="source">J Med Chem</span><span class="year" tagx="year" title="year">2016</span>;<span class="volume" tagx="volume" title="volume">59</span>:<span class="fpage" tagx="fpage" title="fpage">3906</span>â€"<span class="lpage" tagx="lpage" title="lpage">19</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27031565">27031565</a></span></span></li> <li tag="ref"><a name="CIT0037" /><span class="label" tagx="label" title="label">37</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Thomas</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mary</span><span class="given-names" tagx="given-names" title="given-names">YS</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Resmi</span><span class="given-names" tagx="given-names" title="given-names">KS</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Two neoteric pyrazole compounds as potential anti-cancer agents: synthesis, electronic structure, physico-chemical properties and docking analysis</span>. <span class="source" tagx="source" title="source">J Mol Struct</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">1181</span>:<span class="fpage" tagx="fpage" title="fpage">455</span>â€"<span class="lpage" tagx="lpage" title="lpage">66</span>.</span></li> <li tag="ref"><a name="CIT0038" /><span class="label" tagx="label" title="label">38</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bennani</span><span class="given-names" tagx="given-names" title="given-names">FE</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Doudach</span><span class="given-names" tagx="given-names" title="given-names">L</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Cherrah</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Overview of recent developments of pyrazole derivatives as an anticancer agent in different cell line</span>. <span class="source" tagx="source" title="source">Bioorg Chem</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">97</span>:<span class="fpage" tagx="fpage" title="fpage">103470</span>â€"<span class="lpage" tagx="lpage" title="lpage">62</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32120072">32120072</a></span></span></li> <li tag="ref"><a name="CIT0039" /><span class="label" tagx="label" title="label">39</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Farooqui</span><span class="given-names" tagx="given-names" title="given-names">AA.</span></span></span><span class="source" tagx="source" title="source">Phytochemicals, signal transduction, and neurological disorders</span>. New York, USA: <span class="publisher-name" tagx="publisher-name" title="publisher-name">Springer Science &amp;amp; Business Media</span>; <span class="year" tagx="year" title="year">2012</span>.</span></li> <li tag="ref"><a name="CIT0040" /><span class="label" tagx="label" title="label">40</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mahapatra</span><span class="given-names" tagx="given-names" title="given-names">DK</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Asati</span><span class="given-names" tagx="given-names" title="given-names">V</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bharti</span><span class="given-names" tagx="given-names" title="given-names">SK.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Chalcones and their therapeutic targets for the management of diabetes: structural and pharmacological perspectives</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2015</span>;<span class="volume" tagx="volume" title="volume">92</span>:<span class="fpage" tagx="fpage" title="fpage">839</span>â€"<span class="lpage" tagx="lpage" title="lpage">65</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25638569">25638569</a></span></span></li> <li tag="ref"><a name="CIT0041" /><span class="label" tagx="label" title="label">41</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Israf</span><span class="given-names" tagx="given-names" title="given-names">DA</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Khaizurin</span><span class="given-names" tagx="given-names" title="given-names">TA</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Syahida</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Cardamonin inhibits COX and iNOS expression via inhibition of p65NF-kB nuclear translocation and Ik-B phosphorylation in RAW 264.7 macrophage cells</span>. <span class="source" tagx="source" title="source">Mol Immunol</span><span class="year" tagx="year" title="year">2007</span>;<span class="volume" tagx="volume" title="volume">44</span>:<span class="fpage" tagx="fpage" title="fpage">673</span>â€"<span class="lpage" tagx="lpage" title="lpage">9</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16777230">16777230</a></span></span></li> <li tag="ref"><a name="CIT0042" /><span class="label" tagx="label" title="label">42</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kantevari</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Addla</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bagul</span><span class="given-names" tagx="given-names" title="given-names">PK</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis and evaluation of novel 2-butyl-4-chloro-1-methylimidazole embedded chalcones and pyrazoles as angiotensin converting enzyme (ACE) inhibitors</span>. <span class="source" tagx="source" title="source">Bioorg Med Chem</span><span class="year" tagx="year" title="year">2011</span>;<span class="volume" tagx="volume" title="volume">19</span>:<span class="fpage" tagx="fpage" title="fpage">4772</span>â€"<span class="lpage" tagx="lpage" title="lpage">81</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21782455">21782455</a></span></span></li> <li tag="ref"><a name="CIT0043" /><span class="label" tagx="label" title="label">43</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Romagnolo</span><span class="given-names" tagx="given-names" title="given-names">DF</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Selmin</span><span class="given-names" tagx="given-names" title="given-names">OI.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Flavonoids and cancer prevention: a review of the evidence</span>. <span class="source" tagx="source" title="source">J Nutr Gerontol Geriatr</span><span class="year" tagx="year" title="year">2012</span>;<span class="volume" tagx="volume" title="volume">31</span>:<span class="fpage" tagx="fpage" title="fpage">206</span>â€"<span class="lpage" tagx="lpage" title="lpage">38</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22888839">22888839</a></span></span></li> <li tag="ref"><a name="CIT0044" /><span class="label" tagx="label" title="label">44</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chen</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">BrÃ¸gger</span><span class="given-names" tagx="given-names" title="given-names">CS</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhai</span><span class="given-names" tagx="given-names" title="given-names">L</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">The novel oxygenated chalcone, 2,4-dimethoxy-4â€²-butoxychalcone, exhibits potent activity against human malaria parasite <i>Plasmodium falciparum</i> inÂ vitro and rodent parasites <i>Plasmodium berghei</i> and <i>Plasmodium yoelii</i> inÂ vivo</span>. <span class="source" tagx="source" title="source">J Infect Dis</span><span class="year" tagx="year" title="year">1997</span>;<span class="volume" tagx="volume" title="volume">176</span>:<span class="fpage" tagx="fpage" title="fpage">1327</span>â€"<span class="lpage" tagx="lpage" title="lpage">33</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9359735">9359735</a></span></span></li> <li tag="ref"><a name="CIT0045" /><span class="label" tagx="label" title="label">45</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Winter</span><span class="given-names" tagx="given-names" title="given-names">E</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gozzi</span><span class="given-names" tagx="given-names" title="given-names">GJ</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chiaradia-Delatorre</span><span class="given-names" tagx="given-names" title="given-names">LD</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Quinoxaline-substituted chalcones as new inhibitors of breast cancer resistance protein ABCG2: polyspecificity at B-ring position</span>. <span class="source" tagx="source" title="source">Drug Des Dev Ther</span><span class="year" tagx="year" title="year">2014</span>;<span class="volume" tagx="volume" title="volume">8</span>:<span class="fpage" tagx="fpage" title="fpage">609</span>â€"<span class="lpage" tagx="lpage" title="lpage">19</span>.</span></li> <li tag="ref"><a name="CIT0046" /><span class="label" tagx="label" title="label">46</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Debarshi</span><span class="given-names" tagx="given-names" title="given-names">KM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sanjay</span><span class="given-names" tagx="given-names" title="given-names">KB</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Vivek</span><span class="given-names" tagx="given-names" title="given-names">A.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Anti-cancer chalcones: structural and molecular target perspectives</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2015</span>;<span class="volume" tagx="volume" title="volume">98</span>:<span class="fpage" tagx="fpage" title="fpage">69</span>â€"<span class="lpage" tagx="lpage" title="lpage">114</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26005917">26005917</a></span></span></li> <li tag="ref"><a name="CIT0047" /><span class="label" tagx="label" title="label">47</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lee</span><span class="given-names" tagx="given-names" title="given-names">YS</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lim</span><span class="given-names" tagx="given-names" title="given-names">SS</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Shin</span><span class="given-names" tagx="given-names" title="given-names">KM</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Anti-angiogenic and anti-tumor activities of 2â€²-hydroxy-4â€²-methoxychalcone</span>. <span class="source" tagx="source" title="source">Biol Pharm Bull</span><span class="year" tagx="year" title="year">2006</span>;<span class="volume" tagx="volume" title="volume">29</span>:<span class="fpage" tagx="fpage" title="fpage">1028</span>â€"<span class="lpage" tagx="lpage" title="lpage">31</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16651739">16651739</a></span></span></li> <li tag="ref"><a name="CIT0048" /><span class="label" tagx="label" title="label">48</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Varinska</span><span class="given-names" tagx="given-names" title="given-names">L</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wijhe</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Belleri</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Anti-angiogenic activity of the flavonoid precursor 4-hydroxychalcone</span>. <span class="source" tagx="source" title="source">Eur J Pharmacol</span><span class="year" tagx="year" title="year">2012</span>;<span class="volume" tagx="volume" title="volume">691</span>:<span class="fpage" tagx="fpage" title="fpage">125</span>â€"<span class="lpage" tagx="lpage" title="lpage">33</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22721615">22721615</a></span></span></li> <li tag="ref"><a name="CIT0049" /><span class="label" tagx="label" title="label">49</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Guo</span><span class="given-names" tagx="given-names" title="given-names">F</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Feng</span><span class="given-names" tagx="given-names" title="given-names">L</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Huang</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Prenylflavone derivatives from <i>Broussonetia papyrifera</i>, inhibit the growth of breast cancer cells inÂ vitro and inÂ vivo</span>. <span class="source" tagx="source" title="source">Phytochem Lett</span><span class="year" tagx="year" title="year">2013</span>;<span class="volume" tagx="volume" title="volume">6</span>:<span class="fpage" tagx="fpage" title="fpage">331</span>â€"<span class="lpage" tagx="lpage" title="lpage">6</span>.</span></li> <li tag="ref"><a name="CIT0050" /><span class="label" tagx="label" title="label">50</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sisko</span><span class="given-names" tagx="given-names" title="given-names">JT</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tucker</span><span class="given-names" tagx="given-names" title="given-names">TJ</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bilodeau</span><span class="given-names" tagx="given-names" title="given-names">MT</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Potent 2-[(pyrimidin-4-yl)amine]-1,3-thiazole-5-carbonitrile-based inhibitors of VEGFR-2 (KDR) kinase</span>. <span class="source" tagx="source" title="source">Bioorg Med Chem Lett</span><span class="year" tagx="year" title="year">2006</span>;<span class="volume" tagx="volume" title="volume">16</span>:<span class="fpage" tagx="fpage" title="fpage">1146</span>â€"<span class="lpage" tagx="lpage" title="lpage">50</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16368234">16368234</a></span></span></li> <li tag="ref"><a name="CIT0051" /><span class="label" tagx="label" title="label">51</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Peng</span><span class="given-names" tagx="given-names" title="given-names">F-W</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Liu</span><span class="given-names" tagx="given-names" title="given-names">D-K</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhang</span><span class="given-names" tagx="given-names" title="given-names">Q-W</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012â€"2016)</span>. <span class="source" tagx="source" title="source">Expert Opin Ther Pat</span><span class="year" tagx="year" title="year">2017</span>;<span class="volume" tagx="volume" title="volume">27</span>:<span class="fpage" tagx="fpage" title="fpage">987</span>â€"<span class="lpage" tagx="lpage" title="lpage">1004</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28621580">28621580</a></span></span></li> <li tag="ref"><a name="CIT0052" /><span class="label" tagx="label" title="label">52</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mainolfi</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Karki</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Liu</span><span class="given-names" tagx="given-names" title="given-names">F</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Anderson</span><span class="given-names" tagx="given-names" title="given-names">K.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Evolution of a new class of VEGFR-2 inhibitors from scaffold morphing and redesign</span>. <span class="source" tagx="source" title="source">ACS Med Chem Lett</span><span class="year" tagx="year" title="year">2016</span>;<span class="volume" tagx="volume" title="volume">7</span>:<span class="fpage" tagx="fpage" title="fpage">363</span>â€"<span class="lpage" tagx="lpage" title="lpage">7</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27096042">27096042</a></span></span></li> <li tag="ref"><a name="CIT0053" /><span class="label" tagx="label" title="label">53</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Matsumoto</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Miyamoto</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hirayama</span><span class="given-names" tagx="given-names" title="given-names">T</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors</span>. <span class="source" tagx="source" title="source">Bioorg Med Chem</span><span class="year" tagx="year" title="year">2013</span>;<span class="volume" tagx="volume" title="volume">21</span>:<span class="fpage" tagx="fpage" title="fpage">7686</span>â€"<span class="lpage" tagx="lpage" title="lpage">98</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24216091">24216091</a></span></span></li> <li tag="ref"><a name="CIT0054" /><span class="label" tagx="label" title="label">54</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Shibuya</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Vascular endothelial growth factor receptor-2: its unique signaling and specific ligand, VEGF-E</span>. <span class="source" tagx="source" title="source">Cancer Sci</span><span class="year" tagx="year" title="year">2003</span>;<span class="volume" tagx="volume" title="volume">94</span>:<span class="fpage" tagx="fpage" title="fpage">751</span>â€"<span class="lpage" tagx="lpage" title="lpage">6</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12967471">12967471</a></span></span></li> <li tag="ref"><a name="CIT0055" /><span class="label" tagx="label" title="label">55</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sun</span><span class="given-names" tagx="given-names" title="given-names">YS.</span></span></span><span class="source" tagx="source" title="source">Cancer Center, South China Institute of Botany, Chinese Academy of Sciences Assignee. Use of 20,40 dihydroxy-60-methoxy-30,50 dimethyl-chalcone for preparing anticancer medicine, Patent</span><span class="patent" tagx="patent" title="patent">CN1454895</span><span class="patent" tagx="patent" title="patent">A</span>; <span class="year" tagx="year" title="year">2003</span>.</span></li> <li tag="ref"><a name="CIT0056" /><span class="label" tagx="label" title="label">56</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rizvi</span><span class="given-names" tagx="given-names" title="given-names">SUF</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Siddiqui</span><span class="given-names" tagx="given-names" title="given-names">HL</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Nisar</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Discovery and molecular docking of quinolyl-thienyl chalcones as anti-angiogenic agents targeting VEGFR-2 tyrosine kinase</span>. <span class="source" tagx="source" title="source">Bioorg Med Chem Lett</span><span class="year" tagx="year" title="year">2012</span>;<span class="volume" tagx="volume" title="volume">22</span>:<span class="fpage" tagx="fpage" title="fpage">942</span>â€"<span class="lpage" tagx="lpage" title="lpage">4</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22200597">22200597</a></span></span></li> <li tag="ref"><a name="CIT0057" /><span class="label" tagx="label" title="label">57</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">Molecular operating environment (MOE), 10. Montreal: Chemical Computing Group Inc.; <span class="year" tagx="year" title="year">2009</span>.</span></li> <li tag="ref"><a name="CIT0058" /><span class="label" tagx="label" title="label">58</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ibrahim</span><span class="given-names" tagx="given-names" title="given-names">MK</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Taghour</span><span class="given-names" tagx="given-names" title="given-names">MS</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Metwaly</span><span class="given-names" tagx="given-names" title="given-names">AM</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Design, synthesis, molecular modeling and anti-proliferative evaluation of novel quinoxaline derivatives as potential DNA intercalators and topoisomerase II inhibitors</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2018</span>;<span class="volume" tagx="volume" title="volume">155</span>:<span class="fpage" tagx="fpage" title="fpage">117</span>â€"<span class="lpage" tagx="lpage" title="lpage">34</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29885574">29885574</a></span></span></li> <li tag="ref"><a name="CIT0059" /><span class="label" tagx="label" title="label">59</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="collab'">collab: DTP selection guidelines;</span></span><span class="year" tagx="year" title="year">2020</span> Available from: <a href="https://dtp.cancer.gov/organization/dscb/compoundSubmission/structureSelection.htm">https://dtp.cancer.gov/organization/dscb/compoundSubmission/structureSelection.htm</a>.</span></li> <li tag="ref"><a name="CIT0060" /><span class="label" tagx="label" title="label">60</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Liu</span><span class="given-names" tagx="given-names" title="given-names">F</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Dawadi</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Maize</span><span class="given-names" tagx="given-names" title="given-names">KM</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Structure-based optimization of pyridoxal 5â€²-phosphate-dependent transaminase enzyme (BioA) inhibitors that target biotin biosynthesis in <i>Mycobacterium tuberculosis</i></span>. <span class="source" tagx="source" title="source">J Med Chem</span><span class="year" tagx="year" title="year">2017</span>;<span class="volume" tagx="volume" title="volume">60</span>:<span class="fpage" tagx="fpage" title="fpage">5507</span>â€"<span class="lpage" tagx="lpage" title="lpage">20</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28594172">28594172</a></span></span></li> <li tag="ref"><a name="CIT0061" /><span class="label" tagx="label" title="label">61</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Monks</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Scudiero</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Skehan</span><span class="given-names" tagx="given-names" title="given-names">P</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines</span>. <span class="source" tagx="source" title="source">J Natl Cancer Inst</span><span class="year" tagx="year" title="year">1991</span>;<span class="volume" tagx="volume" title="volume">83</span>:<span class="fpage" tagx="fpage" title="fpage">757</span>â€"<span class="lpage" tagx="lpage" title="lpage">66</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2041050">2041050</a></span></span></li> <li tag="ref"><a name="CIT0062" /><span class="label" tagx="label" title="label">62</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wang</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lenardo</span><span class="given-names" tagx="given-names" title="given-names">MJ.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Roles of caspases in apoptosis, development, and cytokine maturation revealed by homozygous gene deficiencies</span>. <span class="source" tagx="source" title="source">J Cell Sci</span><span class="year" tagx="year" title="year">2000</span>;<span class="volume" tagx="volume" title="volume">113</span>:<span class="fpage" tagx="fpage" title="fpage">753</span>â€"<span class="lpage" tagx="lpage" title="lpage">7</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10671365">10671365</a></span></span></li> <li tag="ref"><a name="CIT0063" /><span class="label" tagx="label" title="label">63</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lo</span><span class="given-names" tagx="given-names" title="given-names">KKW</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lee</span><span class="given-names" tagx="given-names" title="given-names">TKM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lau</span><span class="given-names" tagx="given-names" title="given-names">JSY</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Luminescent biological probes derived from ruthenium(II) estradiol polypyridine complexes</span>. <span class="source" tagx="source" title="source">Inorg Chem</span><span class="year" tagx="year" title="year">2008</span>;<span class="volume" tagx="volume" title="volume">47</span>:<span class="fpage" tagx="fpage" title="fpage">200</span>â€"<span class="lpage" tagx="lpage" title="lpage">8</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18067284">18067284</a></span></span></li> </ul> </div> </div>  </body></html>